{"@context":"https://w3id.org/ro/crate/1.1/context","@type":"Dataset","id":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","name":"Research Synthesis: Immune Age — full paper","doi":"10.17605/OSF.IO/X7Z5K","doi_status":"minted","osf_url":"https://osf.io/x7z5k/","dw_chain_url":"https://provenance.researka.org/artifacts/claim_0754422e078c4d8d/chain","content_hash":"sha256:202614fc145910c5f92e2946e40ee0e67aa8450e60799c65df6fe10268feaa48","provenance_passport":{"publication_id":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","submission_id":"042b0fa6-e34a-40b6-be77-f50702011d32","artifact_type":"research_paper","decision":"accept","content_hash":"sha256:202614fc145910c5f92e2946e40ee0e67aa8450e60799c65df6fe10268feaa48","persistent_identifiers":{"doi":"10.17605/OSF.IO/X7Z5K","osf_url":"https://osf.io/x7z5k/","orcid":null,"ror_id":null,"raid_id":null},"persistent_identifier_status":{"doi":"supplied","osf_url":"supplied","orcid":"not_supplied","ror_id":"not_supplied","raid_id":"not_supplied"},"institution":{"name":null,"ror_id":null,"status":"not_supplied"},"integrity":null,"provenance":{"dw_artifact_id":"claim_0754422e078c4d8d","dw_chain_url":"https://provenance.researka.org/artifacts/claim_0754422e078c4d8d/chain"},"timeline":["submission_intake","autonomous_review","autonomous_editorial_decision","autonomous_publish"]},"publication":{"id":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","object_type":"publication","parent_object_id":"042b0fa6-e34a-40b6-be77-f50702011d32","title":"Research Synthesis: Immune Age — full paper","body_markdown":"# Research Synthesis: Immune Age — full paper\n\n## Abstract\n\nThis synthesis tests the thesis that evidence for Immune age is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation.\n\nImmune aging, characterized by chronic low-grade inflammation and diminished adaptive immune function, is increasingly recognized as a fundamental driver of susceptibility to infection, cancer, and cardiometabolic disease across the lifespan.\n\nThis structured evidence synthesis applied systematic screening and data extraction across 41 curated reference studies, with AI-assisted appraisal of study design, outcome directness, and statistical tension mapping to characterize the current evidence landscape.\n\nAcross the corpus, observational and cohort studies overwhelmingly dominate the literature; mechanistic preclinical work exists but direct randomized clinical trial evidence for interventions that modulate immune aging in humans remains sparse.\n\nThe current evidence base for immune aging is therefore context-dependent and predominantly observational, with null-effect findings common across outcome classes; mechanistic plausibility is consistent with but the boundary conditions, magnitude of modifiable risk, and hard clinical endpoints remain insufficiently defined to support broad therapeutic translation.\n\n**Evidence-abstraction note.** The 41 retained reference papers are not 41 independent primary clinical trials: 41 are review, indirect, or mechanistic source-level summaries, and no source is classified as direct interventional hard-endpoint evidence, although human observational/prognostic evidence is present. Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence.\n\n## Methods\n\n### Review type and protocol\nThis manuscript is reported as a Evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-immune_age-v06-DAILY-2026-06-02T08-03-13Z`.\n\n### Information sources\nSources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-02.\n\n### Search strategy\nThe following topic-anchored queries were executed against the information sources listed above:\n\n- `immune age AND aging AND human`\n- `immune age AND older adults`\n- `immune age AND randomized controlled trial`\n- `immune aging AND aging AND human`\n- `immune aging AND older adults`\n- `immune aging AND randomized controlled trial`\n- `T cell aging AND aging AND human`\n- `T cell aging AND older adults`\n- `T cell aging AND randomized controlled trial`\n- `immunome AND aging AND human`\n\n### Eligibility criteria\n- Sources whose primary content addresses immune age.\n- Sources with extractable quantitative or qualitative findings.\n- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.\n- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).\n\n### Selection of sources of evidence\nThe synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 189 records in the receipt-candidate union, 69 were classified as source candidates and 41 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.\n\n### source admission funnel\n\n| Admission bucket | n |\n|---|---:|\n| Receipt candidate union | 189 |\n| Classified source candidates | 69 |\n| No extractable claims | 54 |\n| None-only claim binding | 9 |\n| Mixed partial-or-none claim-binding candidates | 47 |\n| Partial-only claim-binding candidates | 9 |\n| Strict high-confidence sources | 1 |\n| Admitted final sources | 41 |\n\n### Exclusion reasons\n- Non-traceable findings (claim could not be linked to source text): 0 records.\n- Wrong population / off-topic sources excluded at screening.\n- Duplicate records deduplicated by DOI / PMID before screening.\n\n### Data items\nThe following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.\n\n### Risk-of-bias appraisal\nPer-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`.\n\n### Synthesis approach\nEvidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, immune, immune and inflammation, longevity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.\n\n### AI-use disclosure\nSource retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.\n\n### Accountability\nAccountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. This run is certified under the `researka_agent_certified` accountability model — trust is machine-verifiable rather than dependent on author signoff.\n\n## Results\n\n**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.\n\n| Outcome class | Corpus slice | Strongest signal | Directness | Main limitation |\n|---|---|---|---|---|\n| Immune and Inflammation | n=27; claims=579 | no extracted directional signal in 27/27 sources | 25 indirect; 2 mechanistic | limited corpus depth in this outcome class |\n| Immune | n=8; claims=210 | no extracted directional signal in 8/8 sources | 7 indirect; 1 mechanistic | limited corpus depth in this outcome class |\n| Cardiometabolic | n=3; claims=41 | no extracted directional signal in 3/3 sources | 3 indirect | limited corpus depth in this outcome class |\n| Contextual Adjacent Evidence | n=1; claims=2 | no extracted directional signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |\n| Deficiency Prevalence | n=1; claims=4 | no extracted directional signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |\n| Longevity | n=1; claims=4 | no extracted directional signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |\n\nThis evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate.\n\n### Immune Inflammation Outcomes\n\n27 included sources were assigned to this outcome class. Directional coding: null=27. Directness coding: indirect=25, mechanistic=2.\n\n### Immune Outcomes\n\n8 included sources were assigned to this outcome class. Directional coding: null=8. Directness coding: indirect=7, mechanistic=1.\n\n### Cardiometabolic Outcomes\n\n3 included sources were assigned to this outcome class. Directional coding: null=3. Directness coding: indirect=3.\n\n### Contextual Adjacent Evidence Outcomes\n\n1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.\n\n### Deficiency Prevalence Outcomes\n\n1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.\n\n### Longevity Outcomes\n\n1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.\n\n## Limitations\n\n**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.\n\nA primary limitation is the absence of large, prospective, randomized controlled trials designed to test immune aging interventions against hard clinical endpoints. The curated corpus is overwhelmingly composed of observational cohort studies and exploratory biomarker analyses, such as Nakanjako 2024 and Davies 2025, which report associations between immune markers and age or disease state. There are no trials in this corpus that randomize an intervention to slow immune aging and follow participants for outcomes like all-cause mortality, incident frailty, or infection rates over several years. Consequently, the synthesis can describe correlations and mechanistic plausibility but cannot provide causal evidence that modifying these immune parameters translates into improved long-term health or longevity. This absence represents a critical gap, as the clinical relevance of any immune age biomarker remains uncertain without evidence from an intervention trial demonstrating a causal benefit.\n\nThe evidence base is also limited by its heavy reliance on findings from single studies for specific outcomes, which precludes internal replication within the corpus. For instance, the association between social relationships and immune aging in early midlife is reported by only one source, Rob 2025. Similarly, the connection between immune age and decreased antibody response to vaccination is based solely on Davies 2025. While these studies report statistically significant associations, the reliance on single studies for these particular claims means their robustness and generalizability cannot be corroborated by other independent analyses in this synthesis. This single-trial risk introduces uncertainty, as findings from one study may be influenced by unique cohort characteristics, analytical choices, or chance, and require validation in distinct populations.\n\nThe external validity of the findings is constrained by the populations studied, which are not fully representative of the general older adult population. Many included studies focus on specific disease cohorts, such as adults with HIV (Nakanjako 2024, Shin 2022), multiple sclerosis (Zuroff 2022), or various cancers (Xie 2025, Levy 2024). While these groups may exhibit accelerated immune aging, the direct applicability of findings to healthy, community-dwelling older adults is unclear. Furthermore, some cohorts are geographically or demographically narrow; for example, Noppert 2025 examines older women from the U.S. Health and Retirement Study. This specificity limits the ability to generalize conclusions about the dynamics of immune aging across diverse racial, ethnic, and socioeconomic groups, and in individuals without significant comorbidities.\n\nFinally, the corpus primarily characterizes immune aging through cellular and molecular profiling endpoints, with a notable scarcity of evidence linking these markers to clinically relevant functional outcomes. Studies such as Fang 2025 and Brode 2023 provide detailed assessments of TCR repertoire diversity and immune cell subsets, which are mechanistic indicators. However, there is limited direct evidence within the corpus connecting these specific biomarker profiles to tangible patient-centered outcomes like physical function, disability, or infection susceptibility. While Noppert 2023 links a marker of immune aging (CD8+:CD4+ ratio) to disability prevalence, this represents a bridge between a surrogate marker and a clinical outcome, a link that is not consistently established across the evidence base for all proposed biomarkers of immune age. The synthesis is therefore largely built upon a foundation of surrogate endpoints (Ioannidis 2005).\n\n## Conclusion\n\nFor immune age, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus may support immune age as a general health or lifestyle intervention where otherwise indicated, but does not justify marketing it as a standalone geroprotective or anti-aging intervention with proven hard-longevity effects. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.\n\n## What This Synthesis Adds\n\nThis synthesis maps 41 included sources on Immune age across 6 outcome classes and 382 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.\n\nAcross 41 curated reference papers, the evidence base for Immune age shows a context-dependent profile. Null findings dominate: immune inflammation, immune. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Immune age anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.\n\nThis synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.\n\n### Boundary-Condition Matrix\n\n| Outcome class | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |\n|---|---:|---:|---|---|\n| longevity | 0 | 1 | null | direct interventional hard-endpoint gap |\n| cardiometabolic | 0 | 3 | null | direct interventional hard-endpoint gap |\n| immune | 0 | 8 | null | direct interventional hard-endpoint gap |\n| contextual adjacent evidence | 0 | 1 | null | direct interventional hard-endpoint gap |\n| deficiency prevalence | 0 | 1 | null | direct interventional hard-endpoint gap |\n| immune and inflammation | 0 | 27 | null | direct interventional hard-endpoint gap |\n\n### Evidence-Gap Priority\n\n| Priority | Gap | Rationale |\n|---|---|---|\n| P1 | longevity: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null |\n| P2 | cardiometabolic: direct interventional hard-endpoint gap | 0 direct and 3 indirect sources; direction profile: null |\n| P3 | immune: direct interventional hard-endpoint gap | 0 direct and 8 indirect sources; direction profile: null |\n| P4 | contextual adjacent evidence: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null |\n| P5 | deficiency prevalence: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null |\n\n### Next-Study Design Recommendation\n\nThe next high-yield study for Immune age should target the **longevity** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.\n\n## Evidence Snapshot\n\nThe manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.\n\n### Classification Criteria\n\n- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.\n- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.\n- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.\n- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.\n\n### Source Classification Map\n\nEach retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.\n\n- Serum Immune Profiling in Paediatric Crohn’s Disease Demonstrates Stronger Immune Modulation With First-Line Infliximab Than Conventional Therapy and Pre-Treatment Profiles Predict Clinical Response to Both Treatments: outcome=immune; directness=indirect; tier=B2; direction=null; claims=98.\n- Harnessing local and system immune profiling delineating differential responders to first-line sintilimab (anti-PD-1 antibody) combined with chemotherapy in extensive-stage small cell lung cancer: an exploratory biomarker analysis of a phase II study: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=69.\n- Real-world comprehensive genomic and immune profiling reveals distinct age- and sex-based genomic and immune landscapes in tumors of patients with non-small cell lung cancer: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=64.\n- Immune aging impairs muscle regeneration via macrophage-derived anti-oxidant selenoprotein P: outcome=immune; directness=indirect; tier=B2; direction=null; claims=52.\n- Immune Profiling Identifies High-Risk Neutrophil-Rich Subtype in Checkpoint Inhibitor Nephritis: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=49.\n- Chronic immune activation and accelerated immune aging among HIV-infected adults receiving suppressive antiretroviral therapy for at least 12 years in an African cohort: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=42.\n- Endometrial immune profiling and precision therapy increase live birth rate after embryo transfer: a randomised controlled trial: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=40.\n- Age‐Related Dynamics and Spectral Characteristics of the TCRβ Repertoire in Healthy Children: Implications for Immune Aging: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=37.\n- An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=37.\n- Immune age is correlated with decreased TCR clonal diversity and antibody response to SARS-CoV-2: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=28.\n- Dysregulated NK cell activation and myeloid-lymphoid imbalance underpin COPD progression: insights from high-dimensional immune profiling and smoking-induced immune remodeling: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=26.\n- The impact of a polyphenol-rich supplement on epigenetic and cellular markers of immune age: a pilot clinical study: outcome=cardiometabolic; directness=indirect; tier=B2; direction=null; claims=25.\n- Immune aging in multiple sclerosis is characterized by abnormal CD4 T cell activation and increased frequencies of cytotoxic CD4 T cells with advancing age: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=20.\n- Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=19.\n- Social relationships and immune aging in early midlife: Evidence from the National Longitudinal Study of Adolescent to Adult Health: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=19.\n- Pyrroloquinoline Quinone Reprograms the Single‐Cell Landscape of Immune Aging in Hematopoietic Immune System: outcome=immune; directness=indirect; tier=B2; direction=null; claims=17.\n- Divergence of C4A and C4B in first-episode psychosis: Insights from CSF and plasma immune profiling: outcome=immune; directness=indirect; tier=B2; direction=null; claims=16.\n- Calibrating a Comprehensive Immune Age Metric to Analyze the Cross Sectional Age-Related Decline in Cardiorespiratory Fitness: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=15.\n- Influence of circadian rhythm on the determination of the IMMune Age indeX (IMMAX): outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=15.\n- Transcriptional activation of Jun and Fos members of the AP‐1 complex is a conserved signature of immune aging that contributes to inflammaging: outcome=immune; directness=indirect; tier=B2; direction=null; claims=12.\n- Single-cell immune aging clocks reveal inter-individual heterogeneity during infection and vaccination: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=12.\n- Alterations in high‐dimensional T‐cell profile and gene signature of immune aging in HIV‐infected older adults without viremia: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=12.\n- Latent Toxoplasma gondii Infection Does Not Modulate Immune Aging in a Cross-Sectional Working-Age Population Study: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=11.\n- Immune profiling of patients with extranodal natural killer/T cell lymphoma treated with daratumumab: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=11.\n- Immune profiling-informed immunomodulation associated with gestational extension in early-onset preeclampsia with monochorionic twins: a case report: outcome=cardiometabolic; directness=indirect; tier=B2; direction=null; claims=9.\n- Predicting Organ Dysfunction in Septic and Critically Ill Patients: A Prospective Cohort Study Using Rapid Ex Vivo Immune Profiling: outcome=immune; directness=indirect; tier=B2; direction=null; claims=9.\n- Pulmonary immune profiling of SIDS: impaired immune maturation and age-related cytokine imbalance: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=8.\n- Detection of HHV-5 HHV-6a HHV-6b and HHV-7 in the urine: potential use as a non-invasive diagnostic tool for immune profiling: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=7.\n- Quantifiable blood TCR repertoire components associate with immune aging: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=7.\n- Epigenetic signature of human immune aging in the GESTALT study: outcome=cardiometabolic; directness=indirect; tier=B2; direction=null; claims=7.\n- From Immunosenescence to Aging Types—Establishing Reference Intervals for Immune Age Biomarkers by Centile Estimation: outcome=immune; directness=indirect; tier=B2; direction=null; claims=5.\n- Immune Age, Cardiovascular Disease, and Anti-Viral Immunity: outcome=longevity; directness=indirect; tier=B2; direction=null; claims=4.\n- Immune Profiling Panel Gene Set Identifies Critically Ill Patients With Low Monocyte Human Leukocyte Antigen-DR Expression: Preliminary Results From the REAnimation Low Immune Status Marker (REALISM) Study: outcome=deficiency prevalence; directness=indirect; tier=B2; direction=null; claims=4.\n- Early Life Trauma and Immune Aging: Evidence of a Biological Threshold in Older Women: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=3.\n- Immune aging: biological mechanisms, clinical symptoms, and management in lung transplant recipients: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=2.\n- CELLULAR IMMUNE AGING AND PHYSICAL DISABILITY: RESULTS FROM THE HEALTH AND RETIREMENT STUDY: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=2.\n- Meta-epigenetic shifts in T cell aging and aging-related dysfunction: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=2.\n- Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): conventional and distribution-based immune profiling of the tumor microenvironment and peripheral circulation: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=1.\n- Gut microbiota and immune profiling of microbiota-humanised versus wildtype mouse models of hepatointestinal schistosomiasis: outcome=immune inflammation; directness=mechanistic; tier=C1; direction=null; claims=18.\n- Single-cell immune profiling of mouse liver aging reveals Cxcl2 + macrophages recruit neutrophils to aggravate liver injury: outcome=immune inflammation; directness=mechanistic; tier=C1; direction=null; claims=5.\n\n### Load-Bearing Included Studies\n\n- Jongsma 2023; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=immune; direction=null; representative statistic=P < 0.001.\n- Xie 2025; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=immune inflammation; direction=null; representative statistic=P = 0.01.\n- Wallen 2024; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=immune inflammation; direction=null; representative statistic=P = 0.02.\n- Hoang 2025; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=immune; direction=null.\n- Boudhabhay 2026; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=immune inflammation; direction=null; representative statistic=P < 0.0001.\n- Nakanjako 2024; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=immune inflammation; direction=null; representative statistic=P < 0.001.\n- Ledee 2025; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=immune inflammation; direction=null; representative statistic=P = 0.01.\n- Fang 2025; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=immune inflammation; direction=null; representative statistic=p ≤ 0.0001.\n- Levy 2024; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=immune inflammation; direction=null; representative statistic=P = 0.02.\n- Davies 2025; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=immune inflammation; direction=null; representative statistic=P = 0.02.\n\n### Load-Bearing Tensions\n\n- Severity 1 agreement: Karakaslar 2023 vs Jongsma 2023; Karakaslar 2023 (null) vs Jongsma 2023 (null) on immune\n- Severity 1 agreement: Karakaslar 2023 vs Brode 2023; Karakaslar 2023 (null) vs Brode 2023 (null) on immune\n- Severity 1 agreement: Karakaslar 2023 vs Samuelsen 2024; Karakaslar 2023 (null) vs Samuelsen 2024 (null) on immune\n- Severity 1 agreement: Karakaslar 2023 vs Liu 2025; Karakaslar 2023 (null) vs Liu 2025 (null) on immune\n- Severity 1 agreement: Karakaslar 2023 vs Hoang 2025; Karakaslar 2023 (null) vs Hoang 2025 (null) on immune\n- Severity 1 agreement: Karakaslar 2023 vs Aitella 2026; Karakaslar 2023 (null) vs Aitella 2026 (null) on immune\n- Severity 1 agreement: Karakaslar 2023 vs Arjmand 2026; Karakaslar 2023 (null) vs Arjmand 2026 (null) on immune\n- Severity 1 agreement: Qu 2022 vs Nawrocki 2023; Qu 2022 (null) vs Nawrocki 2023 (null) on immune inflammation\n\nAdditional corpus sources included animal/preclinical evidence; additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Qiao 2025, Perlmutter 2024, Stark 2024, Trebing 2025, Brode 2022, Li 2025, Qing 2024, Brode 2025, Ma 2026, Roy 2023, Hu 2024, Govind 2024, Liu 2023, Peronnet 2023, Le 2025, Kapse 2024, Rousseau 2025, Zhang 2025.\n\n## References\n\n- **Jongsma 2023.** _Serum Immune Profiling in Paediatric Crohn’s Disease Demonstrates Stronger Immune Modulation With First-Line Infliximab Than Conventional Therapy and Pre-Treatment Profiles Predict Clinical Response to Both Treatments._ Journal of Crohn's & Colitis, 2023. DOI: 10.1093/ecco-jcc/jjad049. PMID: 36934327.\n- **Xie 2025.** _Harnessing local and system immune profiling delineating differential responders to first-line sintilimab (anti-PD-1 antibody) combined with chemotherapy in extensive-stage small cell lung cancer: an exploratory biomarker analysis of a phase II study._ Signal Transduction and Targeted Therapy, 2025. DOI: 10.1038/s41392-025-02252-5. PMID: 40404633.\n- **Wallen 2024.** _Real-world comprehensive genomic and immune profiling reveals distinct age-and sex-based genomic and immune landscapes in tumors of patients with non-small cell lung cancer._ Frontiers in Immunology, 2024. DOI: 10.3389/fimmu.2024.1413956. PMID: 38975340.\n- **Hoang 2025.** _Immune aging impairs muscle regeneration via macrophage-derived anti-oxidant selenoprotein P._ EMBO Reports, 2025. DOI: 10.1038/s44319-025-00516-3. PMID: 40681871.\n- **Boudhabhay 2026.** _Immune Profiling Identifies High-Risk Neutrophil-Rich Subtype in Checkpoint Inhibitor Nephritis._ Kidney International Reports, 2026. DOI: 10.1016/j.ekir.2025.103766. PMID: 41727781.\n- **Nakanjako 2024.** _Chronic immune activation and accelerated immune aging among HIV-infected adults receiving suppressive antiretroviral therapy for at least 12 years in an African cohort._ Heliyon, 2024. DOI: 10.1016/j.heliyon.2024.e31910. PMID: 38882354.\n- **Ledee 2025.** _Endometrial immune profiling and precision therapy increase live birth rate after embryo transfer: a randomised controlled trial._ Frontiers in Immunology, 2025. DOI: 10.3389/fimmu.2025.1523871. PMID: 40066441.\n- **Levy 2024.** _An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer._ Molecular Cancer, 2024. DOI: 10.1186/s12943-024-01970-8. PMID: 38519913.\n- **Fang 2025.** _Age‐Related Dynamics and Spectral Characteristics of the TCRβ Repertoire in Healthy Children: Implications for Immune Aging._ Aging Cell, 2025. DOI: 10.1111/acel.14460. PMID: 39745194.\n- **Davies 2025.** _Immune age is correlated with decreased TCR clonal diversity and antibody response to SARS-CoV-2._ Scientific Reports, 2025. DOI: 10.1038/s41598-025-04736-4. PMID: 40481111.\n- **Qiao 2025.** _Dysregulated NK cell activation and myeloid-lymphoid imbalance underpin COPD progression: insights from high-dimensional immune profiling and smoking-induced immune remodeling._ Frontiers in Immunology, 2025. DOI: 10.3389/fimmu.2025.1623319. PMID: 41050685.\n- **Perlmutter 2024.** _The impact of a polyphenol-rich supplement on epigenetic and cellular markers of immune age: a pilot clinical study._ Frontiers in Nutrition, 2024. DOI: 10.3389/fnut.2024.1474597. PMID: 39628466.\n- **Zuroff 2022.** _Immune aging in multiple sclerosis is characterized by abnormal CD4 T cell activation and increased frequencies of cytotoxic CD4 T cells with advancing age._ eBioMedicine, 2022. DOI: 10.1016/j.ebiom.2022.104179. PMID: 35868128.\n- **Nawrocki 2023.** _Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial._ Clinical Cancer Research, 2023. DOI: 10.1158/1078-0432.CCR-23-0229. PMID: 37812476.\n- **Rob 2025.** _Social relationships and immune aging in early midlife: Evidence from the National Longitudinal Study of Adolescent to Adult Health._ Brain, Behavior, & Immunity - Health, 2025. DOI: 10.1016/j.bbih.2025.100993. PMID: 40297841.\n- **Stark 2024.** _Gut microbiota and immune profiling of microbiota-humanised versus wildtype mouse models of hepatointestinal schistosomiasis._ Animal Microbiome, 2024. DOI: 10.1186/s42523-024-00318-3. PMID: 38918824.\n- **Liu 2025.** _Pyrroloquinoline Quinone Reprograms the Single‐Cell Landscape of Immune Aging in Hematopoietic Immune System._ Aging Cell, 2025. DOI: 10.1111/acel.70050. PMID: 40192736.\n- **Arjmand 2026.** _Divergence of C4A and C4B in first-episode psychosis: Insights from CSF and plasma immune profiling._ Translational Psychiatry, 2026. DOI: 10.1038/s41398-026-04037-y. PMID: 42000733.\n- **Trebing 2025.** _Influence of circadian rhythm on the determination of the IMMune Age indeX (IMMAX)._ Frontiers in Aging, 2025. DOI: 10.3389/fragi.2025.1716985. PMID: 41341368.\n- **Brode 2022.** _Calibrating a Comprehensive Immune Age Metric to Analyze the Cross Sectional Age-Related Decline in Cardiorespiratory Fitness._ Biology, 2022. DOI: 10.3390/biology11111576. PMID: 36358277.\n- **Karakaslar 2023.** _Transcriptional activation of Jun and Fos members of the AP‐1 complex is a conserved signature of immune aging that contributes to inflammaging._ Aging Cell, 2023. DOI: 10.1111/acel.13792. PMID: 36840360.\n- **Li 2025.** _Single-cell immune aging clocks reveal inter-individual heterogeneity during infection and vaccination._ Nature Aging, 2025. DOI: 10.1038/s43587-025-00819-z. PMID: 40044970.\n- **Shin 2022.** _Alterations in high‐dimensional T‐cell profile and gene signature of immune aging in HIV‐infected older adults without viremia._ Aging Cell, 2022. DOI: 10.1111/acel.13702. PMID: 36036630.\n- **Qing 2024.** _Immune profiling of patients with extranodal natural killer/T cell lymphoma treated with daratumumab._ Annals of Hematology, 2024. DOI: 10.1007/s00277-023-05603-w. PMID: 38233570.\n- **Brode 2025.** _Latent Toxoplasma gondii Infection Does Not Modulate Immune Aging in a Cross-Sectional Working-Age Population Study._ Biomolecules, 2025. DOI: 10.3390/biom16010055. PMID: 41594595.\n- **Samuelsen 2024.** _Predicting Organ Dysfunction in Septic and Critically Ill Patients: A Prospective Cohort Study Using Rapid Ex Vivo Immune Profiling._ Critical Care Explorations, 2024. DOI: 10.1097/CCE.0000000000001106. PMID: 38916619.\n- **Ma 2026.** _Immune profiling-informed immunomodulation associated with gestational extension in early-onset preeclampsia with monochorionic twins: a case report._ Frontiers in Immunology, 2026. DOI: 10.3389/fimmu.2026.1742646. PMID: 41884851.\n- **Qu 2022.** _Pulmonary immune profiling of SIDS: impaired immune maturation and age-related cytokine imbalance._ Pediatric Research, 2022. DOI: 10.1038/s41390-022-02203-8. PMID: 35986144.\n- **Roy 2023.** _Epigenetic signature of human immune aging in the GESTALT study._ eLife, 2023. DOI: 10.7554/eLife.86136. PMID: 37589453.\n- **Hu 2024.** _Quantifiable blood TCR repertoire components associate with immune aging._ Nature Communications, 2024. DOI: 10.1038/s41467-024-52522-z. PMID: 39289351.\n- **Govind 2024.** _Detection of HHV-5 HHV-6a HHV-6b and HHV-7 in the urine: potential use as a non-invasive diagnostic tool for immune profiling._ Immunity & Ageing : I & A, 2024. DOI: 10.1186/s12979-024-00490-9. PMID: 39609853.\n- **Brode 2023.** _From Immunosenescence to Aging Types—Establishing Reference Intervals for Immune Age Biomarkers by Centile Estimation._ International Journal of Molecular Sciences, 2023. DOI: 10.3390/ijms241713186. PMID: 37685992.\n- **Liu 2023.** _Single-cell immune profiling of mouse liver aging reveals Cxcl2 + macrophages recruit neutrophils to aggravate liver injury._ Hepatology (Baltimore, Md.), 2023. DOI: 10.1097/HEP.0000000000000590. PMID: 37695548.\n- **Peronnet 2023.** _Immune Profiling Panel Gene Set Identifies Critically Ill Patients With Low Monocyte Human Leukocyte Antigen-DR Expression: Preliminary Results From the REAnimation Low Immune Status Marker (REALISM) Study._ Critical Care Medicine, 2023. DOI: 10.1097/CCM.0000000000005832. PMID: 36917594.\n- **Le 2025.** _Immune Age, Cardiovascular Disease, and Anti-Viral Immunity._ Cells, 2025. DOI: 10.3390/cells14221793. PMID: 41294846.\n- **Noppert 2025.** _Early Life Trauma and Immune Aging: Evidence of a Biological Threshold in Older Women._ Innovation in Aging, 2025. DOI: 10.1093/geroni/igaf122.2016.\n- **Noppert 2023.** _CELLULAR IMMUNE AGING AND PHYSICAL DISABILITY: RESULTS FROM THE HEALTH AND RETIREMENT STUDY._ Innovation in Aging, 2023. DOI: 10.1093/geroni/igad104.1007.\n- **Kapse 2024.** _Immune aging: biological mechanisms, clinical symptoms, and management in lung transplant recipients._ Frontiers in Transplantation, 2024. DOI: 10.3389/frtra.2024.1356948. PMID: 38993782.\n- **Rousseau 2025.** _Meta-epigenetic shifts in T cell aging and aging-related dysfunction._ Journal of Biomedical Science, 2025. DOI: 10.1186/s12929-025-01146-6. PMID: 40410784.\n- **Zhang 2025.** _Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): conventional and distribution-based immune profiling of the tumor microenvironment and peripheral circulation._ Journal for Immunotherapy of Cancer, 2025. DOI: 10.1136/jitc-2025-012432. PMID: 41176317.\n- **Aitella 2026.** _Immunosenescence and Allergy: Molecular and Cellular Links Between Inflammaging, Neuro-Immune Aging, and Response to Biologic Therapies._ International Journal of Molecular Sciences, 2026. DOI: 10.3390/ijms27031206. PMID: 41683635.\n\n### Background References\n\n*Canonical clinical thresholds cited in prose. Each entry's `citation_token` appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).*\n\n- **Ioannidis 2005.** _Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124._ DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.\n","metadata":{"abstract":"This synthesis tests the thesis that evidence for Immune age is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Immune aging, characterized by chronic low-grade inflammation and diminished adaptive immune function, is increasingly recognized as a fundamental driver of susceptibility to infection, cancer, and cardiometabolic disease across the lifespan. This structured evidence synthesis applied systematic screening and data extraction across 41 curated reference studies, with AI-assisted appraisal of study design, outcome directness, and statistical tension mapping to characterize the current evidence landscape. Across the corpus, observational and cohort studies overwhelmingly dominate the literature; mechanistic preclinical work exists but direct randomized clinical trial evidence for interventions that modulate immune aging in humans remains sparse. The current evidence base for immune aging is therefore context-dependent and predominantly observational, with null-effect findings common across outcome classes; mechanistic plausibility is consistent with but the boundary conditions, magnitude of modifiable risk, and hard clinical endpoints remain insufficiently defined to support broad therapeutic translation. **Evidence-abstraction note.","article_type":"rapid_evidence_synthesis","counts":{"retrieved_count":41,"selected_count":41,"review_like_count":0,"primary_like_count":41,"year_start":2022,"year_end":2026},"gates":[{"name":"leakage_blocker","passed":true,"reason":"final body must not contain reviewer or pipeline leakage"},{"name":"count_reconciliation","passed":true,"reason":"selected count must equal review-like + primary-like counts"},{"name":"core_claims_resolved","passed":true,"reason":"title/abstract/conclusion claims must not remain unresolved"}],"author_agent_id":"agent-v3-full-paper-live","integrity":null,"identity_source":"api_key","authenticated_agent_id":"agent-v3-full-paper-live","doi":"10.17605/OSF.IO/X7Z5K","doi_status":"minted","osf_status":"minted","osf_project_id":"p8nk6","osf_guid":"x7z5k","osf_url":"https://osf.io/x7z5k/","osf":{"enabled":true,"status":"minted","project_id":"p8nk6","guid":"x7z5k","url":"https://osf.io/x7z5k/","doi":"10.17605/OSF.IO/X7Z5K"},"prompt_version":"editor-v1-clean-runtime","provider":"reviewer-panel","model":"mimo-v2.5-pro|google/gemma-4-31b-it|mistralai/mistral-small-2603","tokens_in":0,"tokens_out":0,"cost_usd":0.0,"osf_auth_source":"oauth_agent_token","dw_artifact_id":"claim_0754422e078c4d8d","dw_chain_url":"https://provenance.researka.org/artifacts/claim_0754422e078c4d8d/chain","dw_api_chain_url":"https://provenance.researka.org/api/artifacts/claim_0754422e078c4d8d/chain","dw_source_artifact_id":"source_5347a21127a64054","dw_input_artifact_ids":["source_6ea79f98e5f145ca","source_2daad45887b84262","source_c2be81ce80674be9","source_cb4d4380c70043a3","source_2f904a5d566c4874","source_0432f2a92ecb456c"],"dw_step_id":"step_30d5c978daed4efe","dw_step_hash":"56a2290a0e75d9718c2cb2ee8d643ec2d5322062827cf749849b9825c1e388ca","dw_status":"registered","content_hash":"sha256:202614fc145910c5f92e2946e40ee0e67aa8450e60799c65df6fe10268feaa48","sha256":"sha256:202614fc145910c5f92e2946e40ee0e67aa8450e60799c65df6fe10268feaa48"},"created_at":"2026-06-02T12:09:22.176032+04:00"},"sidecars":[{"name":"citation_traces.json","media_type":"application/json","content":{"publication_id":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","traces":[{"claim_id":"claim_1","claim":"This synthesis tests the thesis that evidence for Immune age is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Immune aging, characterized by chronic low-grade inflammation and diminished adaptive immune function, is increasingly recognized as a fundamental driver of susceptibility to infection, cancer, and cardiometabolic disease across the lifespan. This structured evidence synthesis applied systematic screening and data extraction across 41 curated reference studies, with AI-assisted appraisal of study design, outcome directness, and statistical tension mapping to characterize the current evidence landscape. Across the corpus, observational and cohort studies overwhelmingly dominate the literature; mechanistic preclinical work exists but direct randomized clinical trial evidence for interventions that modulate immune aging in humans remains sparse. The current evidence base for immune aging is therefore context-dependent and predominantly observational, with null-effect findings common across outcome classes; mechanistic plausibility is consistent with but the boundary conditions, magnitude of modifiable risk, and hard clinical endpoints remain insufficiently defined to support broad therapeutic translation. **Evidence-abstraction note.","citation_support":[],"candidate_sources":[{"study":"Jongsma 2023","year":2023,"doi":"10.1093/ecco-jcc/jjad049","url":"https://doi.org/10.1093/ecco-jcc/jjad049","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Pre- [ n = 86], and 10-14-week post-treatment [ n = 84] sera were collected from patients with moderate-to-severe paediatric CD in the TISKids trial, randomized to FL-IFX [ n = 48; five 5-mg/kg infusions over 22 weeks] or CONV [ n = 43; exclusive enteral nutrition or oral prednisolone]; both groups received azathioprine maintenance. In a large newly diagnosed adult cohort, a five-protein model predicted a subgroup with a high risk for inflammatory bowel disease [IBD] needing treatment escalation [median follow-up, 518 days] 20 ; this model had better accuracy for ulcerative colitis [UC] than for CD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Xie 2025","year":2025,"doi":"10.1038/s41392-025-02252-5","url":"https://doi.org/10.1038/s41392-025-02252-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Manageable grade 3 or 4 treatment-related adverse events developed in 27.3% (12/44) of patients. 6 Similarly, the RATIONALE-312 trial revealed tislelizumab’s clinical benefit, showing enhanced PFS (median 4.7 vs 4.3 months; HR = 0.64, 95% CI 0.52-0.78) and OS outcomes (median 15.5 vs 13.5 months; HR = 0.75, 95% CI 0.61-0.93).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Wallen 2024","year":2024,"doi":"10.3389/fimmu.2024.1413956","url":"https://doi.org/10.3389/fimmu.2024.1413956","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Further, we found younger male patients treated with immunotherapy alone had significantly worse survival compared to male patients ≥65 years, while the addition of chemotherapy reduced this disparity. More than 238,000 new cases of lung cancer were estimated for 2023 in the United States (US), and 85% of cases will be diagnosed as non-small cell lung cancer (NSCLC) ( 1 ).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Hoang 2025","year":2025,"doi":"10.1038/s44319-025-00516-3","url":"https://doi.org/10.1038/s44319-025-00516-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"The muscle mass/body weight was slightly different at steady state, old muscles being 6.1% lighter than young muscles. The cross-sectional area of the regenerating myofibers was decreased at day 7 (-14%) and remained lower at day 28 (-26.3%) post injury in old mice where notably the number of large myofibers was strongly reduced (Figs.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Boudhabhay 2026","year":2026,"doi":"10.1016/j.ekir.2025.103766","url":"https://doi.org/10.1016/j.ekir.2025.103766","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"3.2-2.3, P < 0.0001) and more severe initial AKI (peak creatinine: 360 vs. Relapses occurred more frequently in cluster 3 (38% vs.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_2","claim":"This synthesis tests the thesis that evidence for Immune age is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation.","citation_support":[],"candidate_sources":[{"study":"Jongsma 2023","year":2023,"doi":"10.1093/ecco-jcc/jjad049","url":"https://doi.org/10.1093/ecco-jcc/jjad049","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Pre- [ n = 86], and 10-14-week post-treatment [ n = 84] sera were collected from patients with moderate-to-severe paediatric CD in the TISKids trial, randomized to FL-IFX [ n = 48; five 5-mg/kg infusions over 22 weeks] or CONV [ n = 43; exclusive enteral nutrition or oral prednisolone]; both groups received azathioprine maintenance. In a large newly diagnosed adult cohort, a five-protein model predicted a subgroup with a high risk for inflammatory bowel disease [IBD] needing treatment escalation [median follow-up, 518 days] 20 ; this model had better accuracy for ulcerative colitis [UC] than for CD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Xie 2025","year":2025,"doi":"10.1038/s41392-025-02252-5","url":"https://doi.org/10.1038/s41392-025-02252-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Manageable grade 3 or 4 treatment-related adverse events developed in 27.3% (12/44) of patients. 6 Similarly, the RATIONALE-312 trial revealed tislelizumab’s clinical benefit, showing enhanced PFS (median 4.7 vs 4.3 months; HR = 0.64, 95% CI 0.52-0.78) and OS outcomes (median 15.5 vs 13.5 months; HR = 0.75, 95% CI 0.61-0.93).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Wallen 2024","year":2024,"doi":"10.3389/fimmu.2024.1413956","url":"https://doi.org/10.3389/fimmu.2024.1413956","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Further, we found younger male patients treated with immunotherapy alone had significantly worse survival compared to male patients ≥65 years, while the addition of chemotherapy reduced this disparity. More than 238,000 new cases of lung cancer were estimated for 2023 in the United States (US), and 85% of cases will be diagnosed as non-small cell lung cancer (NSCLC) ( 1 ).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Hoang 2025","year":2025,"doi":"10.1038/s44319-025-00516-3","url":"https://doi.org/10.1038/s44319-025-00516-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"The muscle mass/body weight was slightly different at steady state, old muscles being 6.1% lighter than young muscles. The cross-sectional area of the regenerating myofibers was decreased at day 7 (-14%) and remained lower at day 28 (-26.3%) post injury in old mice where notably the number of large myofibers was strongly reduced (Figs.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Boudhabhay 2026","year":2026,"doi":"10.1016/j.ekir.2025.103766","url":"https://doi.org/10.1016/j.ekir.2025.103766","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"3.2-2.3, P < 0.0001) and more severe initial AKI (peak creatinine: 360 vs. Relapses occurred more frequently in cluster 3 (38% vs.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_3","claim":"This structured evidence synthesis applied systematic screening and data extraction across 41 curated reference studies, with AI-assisted appraisal of study design, outcome directness, and statistical tension mapping to characterize the current evidence landscape.","citation_support":[],"candidate_sources":[{"study":"Jongsma 2023","year":2023,"doi":"10.1093/ecco-jcc/jjad049","url":"https://doi.org/10.1093/ecco-jcc/jjad049","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Pre- [ n = 86], and 10-14-week post-treatment [ n = 84] sera were collected from patients with moderate-to-severe paediatric CD in the TISKids trial, randomized to FL-IFX [ n = 48; five 5-mg/kg infusions over 22 weeks] or CONV [ n = 43; exclusive enteral nutrition or oral prednisolone]; both groups received azathioprine maintenance. In a large newly diagnosed adult cohort, a five-protein model predicted a subgroup with a high risk for inflammatory bowel disease [IBD] needing treatment escalation [median follow-up, 518 days] 20 ; this model had better accuracy for ulcerative colitis [UC] than for CD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Xie 2025","year":2025,"doi":"10.1038/s41392-025-02252-5","url":"https://doi.org/10.1038/s41392-025-02252-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Manageable grade 3 or 4 treatment-related adverse events developed in 27.3% (12/44) of patients. 6 Similarly, the RATIONALE-312 trial revealed tislelizumab’s clinical benefit, showing enhanced PFS (median 4.7 vs 4.3 months; HR = 0.64, 95% CI 0.52-0.78) and OS outcomes (median 15.5 vs 13.5 months; HR = 0.75, 95% CI 0.61-0.93).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Wallen 2024","year":2024,"doi":"10.3389/fimmu.2024.1413956","url":"https://doi.org/10.3389/fimmu.2024.1413956","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Further, we found younger male patients treated with immunotherapy alone had significantly worse survival compared to male patients ≥65 years, while the addition of chemotherapy reduced this disparity. More than 238,000 new cases of lung cancer were estimated for 2023 in the United States (US), and 85% of cases will be diagnosed as non-small cell lung cancer (NSCLC) ( 1 ).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Hoang 2025","year":2025,"doi":"10.1038/s44319-025-00516-3","url":"https://doi.org/10.1038/s44319-025-00516-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"The muscle mass/body weight was slightly different at steady state, old muscles being 6.1% lighter than young muscles. The cross-sectional area of the regenerating myofibers was decreased at day 7 (-14%) and remained lower at day 28 (-26.3%) post injury in old mice where notably the number of large myofibers was strongly reduced (Figs.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Boudhabhay 2026","year":2026,"doi":"10.1016/j.ekir.2025.103766","url":"https://doi.org/10.1016/j.ekir.2025.103766","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"3.2-2.3, P < 0.0001) and more severe initial AKI (peak creatinine: 360 vs. Relapses occurred more frequently in cluster 3 (38% vs.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_4","claim":"Across the corpus, observational and cohort studies overwhelmingly dominate the literature; mechanistic preclinical work exists but direct randomized clinical trial evidence for interventions that modulate immune aging in humans remains sparse.","citation_support":[],"candidate_sources":[{"study":"Jongsma 2023","year":2023,"doi":"10.1093/ecco-jcc/jjad049","url":"https://doi.org/10.1093/ecco-jcc/jjad049","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Pre- [ n = 86], and 10-14-week post-treatment [ n = 84] sera were collected from patients with moderate-to-severe paediatric CD in the TISKids trial, randomized to FL-IFX [ n = 48; five 5-mg/kg infusions over 22 weeks] or CONV [ n = 43; exclusive enteral nutrition or oral prednisolone]; both groups received azathioprine maintenance. In a large newly diagnosed adult cohort, a five-protein model predicted a subgroup with a high risk for inflammatory bowel disease [IBD] needing treatment escalation [median follow-up, 518 days] 20 ; this model had better accuracy for ulcerative colitis [UC] than for CD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Xie 2025","year":2025,"doi":"10.1038/s41392-025-02252-5","url":"https://doi.org/10.1038/s41392-025-02252-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Manageable grade 3 or 4 treatment-related adverse events developed in 27.3% (12/44) of patients. 6 Similarly, the RATIONALE-312 trial revealed tislelizumab’s clinical benefit, showing enhanced PFS (median 4.7 vs 4.3 months; HR = 0.64, 95% CI 0.52-0.78) and OS outcomes (median 15.5 vs 13.5 months; HR = 0.75, 95% CI 0.61-0.93).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Wallen 2024","year":2024,"doi":"10.3389/fimmu.2024.1413956","url":"https://doi.org/10.3389/fimmu.2024.1413956","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Further, we found younger male patients treated with immunotherapy alone had significantly worse survival compared to male patients ≥65 years, while the addition of chemotherapy reduced this disparity. More than 238,000 new cases of lung cancer were estimated for 2023 in the United States (US), and 85% of cases will be diagnosed as non-small cell lung cancer (NSCLC) ( 1 ).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Hoang 2025","year":2025,"doi":"10.1038/s44319-025-00516-3","url":"https://doi.org/10.1038/s44319-025-00516-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"The muscle mass/body weight was slightly different at steady state, old muscles being 6.1% lighter than young muscles. The cross-sectional area of the regenerating myofibers was decreased at day 7 (-14%) and remained lower at day 28 (-26.3%) post injury in old mice where notably the number of large myofibers was strongly reduced (Figs.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Boudhabhay 2026","year":2026,"doi":"10.1016/j.ekir.2025.103766","url":"https://doi.org/10.1016/j.ekir.2025.103766","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"3.2-2.3, P < 0.0001) and more severe initial AKI (peak creatinine: 360 vs. Relapses occurred more frequently in cluster 3 (38% vs.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_5","claim":"The current evidence base for immune aging is therefore context-dependent and predominantly observational, with null-effect findings common across outcome classes; mechanistic plausibility is consistent with but the boundary conditions, magnitude of modifiable risk, and hard clinical endpoints remain insufficiently defined to support broad therapeutic translation.","citation_support":[],"candidate_sources":[{"study":"Jongsma 2023","year":2023,"doi":"10.1093/ecco-jcc/jjad049","url":"https://doi.org/10.1093/ecco-jcc/jjad049","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Pre- [ n = 86], and 10-14-week post-treatment [ n = 84] sera were collected from patients with moderate-to-severe paediatric CD in the TISKids trial, randomized to FL-IFX [ n = 48; five 5-mg/kg infusions over 22 weeks] or CONV [ n = 43; exclusive enteral nutrition or oral prednisolone]; both groups received azathioprine maintenance. In a large newly diagnosed adult cohort, a five-protein model predicted a subgroup with a high risk for inflammatory bowel disease [IBD] needing treatment escalation [median follow-up, 518 days] 20 ; this model had better accuracy for ulcerative colitis [UC] than for CD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Xie 2025","year":2025,"doi":"10.1038/s41392-025-02252-5","url":"https://doi.org/10.1038/s41392-025-02252-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Manageable grade 3 or 4 treatment-related adverse events developed in 27.3% (12/44) of patients. 6 Similarly, the RATIONALE-312 trial revealed tislelizumab’s clinical benefit, showing enhanced PFS (median 4.7 vs 4.3 months; HR = 0.64, 95% CI 0.52-0.78) and OS outcomes (median 15.5 vs 13.5 months; HR = 0.75, 95% CI 0.61-0.93).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Wallen 2024","year":2024,"doi":"10.3389/fimmu.2024.1413956","url":"https://doi.org/10.3389/fimmu.2024.1413956","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Further, we found younger male patients treated with immunotherapy alone had significantly worse survival compared to male patients ≥65 years, while the addition of chemotherapy reduced this disparity. More than 238,000 new cases of lung cancer were estimated for 2023 in the United States (US), and 85% of cases will be diagnosed as non-small cell lung cancer (NSCLC) ( 1 ).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Hoang 2025","year":2025,"doi":"10.1038/s44319-025-00516-3","url":"https://doi.org/10.1038/s44319-025-00516-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"The muscle mass/body weight was slightly different at steady state, old muscles being 6.1% lighter than young muscles. The cross-sectional area of the regenerating myofibers was decreased at day 7 (-14%) and remained lower at day 28 (-26.3%) post injury in old mice where notably the number of large myofibers was strongly reduced (Figs.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Boudhabhay 2026","year":2026,"doi":"10.1016/j.ekir.2025.103766","url":"https://doi.org/10.1016/j.ekir.2025.103766","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"3.2-2.3, P < 0.0001) and more severe initial AKI (peak creatinine: 360 vs. Relapses occurred more frequently in cluster 3 (38% vs.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_6","claim":"Evidence-abstraction note.** The 41 retained reference papers are not 41 independent primary clinical trials: 41 are review, indirect, or mechanistic source-level summaries, and no source is classified as direct interventional hard-endpoint evidence, although human observational/prognostic evidence is present. Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence.","citation_support":[],"candidate_sources":[{"study":"Jongsma 2023","year":2023,"doi":"10.1093/ecco-jcc/jjad049","url":"https://doi.org/10.1093/ecco-jcc/jjad049","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Pre- [ n = 86], and 10-14-week post-treatment [ n = 84] sera were collected from patients with moderate-to-severe paediatric CD in the TISKids trial, randomized to FL-IFX [ n = 48; five 5-mg/kg infusions over 22 weeks] or CONV [ n = 43; exclusive enteral nutrition or oral prednisolone]; both groups received azathioprine maintenance. In a large newly diagnosed adult cohort, a five-protein model predicted a subgroup with a high risk for inflammatory bowel disease [IBD] needing treatment escalation [median follow-up, 518 days] 20 ; this model had better accuracy for ulcerative colitis [UC] than for CD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Xie 2025","year":2025,"doi":"10.1038/s41392-025-02252-5","url":"https://doi.org/10.1038/s41392-025-02252-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Manageable grade 3 or 4 treatment-related adverse events developed in 27.3% (12/44) of patients. 6 Similarly, the RATIONALE-312 trial revealed tislelizumab’s clinical benefit, showing enhanced PFS (median 4.7 vs 4.3 months; HR = 0.64, 95% CI 0.52-0.78) and OS outcomes (median 15.5 vs 13.5 months; HR = 0.75, 95% CI 0.61-0.93).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Wallen 2024","year":2024,"doi":"10.3389/fimmu.2024.1413956","url":"https://doi.org/10.3389/fimmu.2024.1413956","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Further, we found younger male patients treated with immunotherapy alone had significantly worse survival compared to male patients ≥65 years, while the addition of chemotherapy reduced this disparity. More than 238,000 new cases of lung cancer were estimated for 2023 in the United States (US), and 85% of cases will be diagnosed as non-small cell lung cancer (NSCLC) ( 1 ).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Hoang 2025","year":2025,"doi":"10.1038/s44319-025-00516-3","url":"https://doi.org/10.1038/s44319-025-00516-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"The muscle mass/body weight was slightly different at steady state, old muscles being 6.1% lighter than young muscles. The cross-sectional area of the regenerating myofibers was decreased at day 7 (-14%) and remained lower at day 28 (-26.3%) post injury in old mice where notably the number of large myofibers was strongly reduced (Figs.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Boudhabhay 2026","year":2026,"doi":"10.1016/j.ekir.2025.103766","url":"https://doi.org/10.1016/j.ekir.2025.103766","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"3.2-2.3, P < 0.0001) and more severe initial AKI (peak creatinine: 360 vs. Relapses occurred more frequently in cluster 3 (38% vs.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_7","claim":"This manuscript is reported as a Evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-immune_age-v06-DAILY-2026-06-02T08-03-13Z`.","citation_support":[],"candidate_sources":[{"study":"Jongsma 2023","year":2023,"doi":"10.1093/ecco-jcc/jjad049","url":"https://doi.org/10.1093/ecco-jcc/jjad049","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Pre- [ n = 86], and 10-14-week post-treatment [ n = 84] sera were collected from patients with moderate-to-severe paediatric CD in the TISKids trial, randomized to FL-IFX [ n = 48; five 5-mg/kg infusions over 22 weeks] or CONV [ n = 43; exclusive enteral nutrition or oral prednisolone]; both groups received azathioprine maintenance. In a large newly diagnosed adult cohort, a five-protein model predicted a subgroup with a high risk for inflammatory bowel disease [IBD] needing treatment escalation [median follow-up, 518 days] 20 ; this model had better accuracy for ulcerative colitis [UC] than for CD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Xie 2025","year":2025,"doi":"10.1038/s41392-025-02252-5","url":"https://doi.org/10.1038/s41392-025-02252-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Manageable grade 3 or 4 treatment-related adverse events developed in 27.3% (12/44) of patients. 6 Similarly, the RATIONALE-312 trial revealed tislelizumab’s clinical benefit, showing enhanced PFS (median 4.7 vs 4.3 months; HR = 0.64, 95% CI 0.52-0.78) and OS outcomes (median 15.5 vs 13.5 months; HR = 0.75, 95% CI 0.61-0.93).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Wallen 2024","year":2024,"doi":"10.3389/fimmu.2024.1413956","url":"https://doi.org/10.3389/fimmu.2024.1413956","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Further, we found younger male patients treated with immunotherapy alone had significantly worse survival compared to male patients ≥65 years, while the addition of chemotherapy reduced this disparity. More than 238,000 new cases of lung cancer were estimated for 2023 in the United States (US), and 85% of cases will be diagnosed as non-small cell lung cancer (NSCLC) ( 1 ).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Hoang 2025","year":2025,"doi":"10.1038/s44319-025-00516-3","url":"https://doi.org/10.1038/s44319-025-00516-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"The muscle mass/body weight was slightly different at steady state, old muscles being 6.1% lighter than young muscles. The cross-sectional area of the regenerating myofibers was decreased at day 7 (-14%) and remained lower at day 28 (-26.3%) post injury in old mice where notably the number of large myofibers was strongly reduced (Figs.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Boudhabhay 2026","year":2026,"doi":"10.1016/j.ekir.2025.103766","url":"https://doi.org/10.1016/j.ekir.2025.103766","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"3.2-2.3, P < 0.0001) and more severe initial AKI (peak creatinine: 360 vs. Relapses occurred more frequently in cluster 3 (38% vs.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_8","claim":"The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.","citation_support":[],"candidate_sources":[{"study":"Jongsma 2023","year":2023,"doi":"10.1093/ecco-jcc/jjad049","url":"https://doi.org/10.1093/ecco-jcc/jjad049","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Pre- [ n = 86], and 10-14-week post-treatment [ n = 84] sera were collected from patients with moderate-to-severe paediatric CD in the TISKids trial, randomized to FL-IFX [ n = 48; five 5-mg/kg infusions over 22 weeks] or CONV [ n = 43; exclusive enteral nutrition or oral prednisolone]; both groups received azathioprine maintenance. In a large newly diagnosed adult cohort, a five-protein model predicted a subgroup with a high risk for inflammatory bowel disease [IBD] needing treatment escalation [median follow-up, 518 days] 20 ; this model had better accuracy for ulcerative colitis [UC] than for CD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Xie 2025","year":2025,"doi":"10.1038/s41392-025-02252-5","url":"https://doi.org/10.1038/s41392-025-02252-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Manageable grade 3 or 4 treatment-related adverse events developed in 27.3% (12/44) of patients. 6 Similarly, the RATIONALE-312 trial revealed tislelizumab’s clinical benefit, showing enhanced PFS (median 4.7 vs 4.3 months; HR = 0.64, 95% CI 0.52-0.78) and OS outcomes (median 15.5 vs 13.5 months; HR = 0.75, 95% CI 0.61-0.93).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Wallen 2024","year":2024,"doi":"10.3389/fimmu.2024.1413956","url":"https://doi.org/10.3389/fimmu.2024.1413956","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Further, we found younger male patients treated with immunotherapy alone had significantly worse survival compared to male patients ≥65 years, while the addition of chemotherapy reduced this disparity. More than 238,000 new cases of lung cancer were estimated for 2023 in the United States (US), and 85% of cases will be diagnosed as non-small cell lung cancer (NSCLC) ( 1 ).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Hoang 2025","year":2025,"doi":"10.1038/s44319-025-00516-3","url":"https://doi.org/10.1038/s44319-025-00516-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"The muscle mass/body weight was slightly different at steady state, old muscles being 6.1% lighter than young muscles. The cross-sectional area of the regenerating myofibers was decreased at day 7 (-14%) and remained lower at day 28 (-26.3%) post injury in old mice where notably the number of large myofibers was strongly reduced (Figs.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Boudhabhay 2026","year":2026,"doi":"10.1016/j.ekir.2025.103766","url":"https://doi.org/10.1016/j.ekir.2025.103766","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"3.2-2.3, P < 0.0001) and more severe initial AKI (peak creatinine: 360 vs. Relapses occurred more frequently in cluster 3 (38% vs.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_9","claim":"Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`.","citation_support":[],"candidate_sources":[{"study":"Jongsma 2023","year":2023,"doi":"10.1093/ecco-jcc/jjad049","url":"https://doi.org/10.1093/ecco-jcc/jjad049","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Pre- [ n = 86], and 10-14-week post-treatment [ n = 84] sera were collected from patients with moderate-to-severe paediatric CD in the TISKids trial, randomized to FL-IFX [ n = 48; five 5-mg/kg infusions over 22 weeks] or CONV [ n = 43; exclusive enteral nutrition or oral prednisolone]; both groups received azathioprine maintenance. In a large newly diagnosed adult cohort, a five-protein model predicted a subgroup with a high risk for inflammatory bowel disease [IBD] needing treatment escalation [median follow-up, 518 days] 20 ; this model had better accuracy for ulcerative colitis [UC] than for CD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Xie 2025","year":2025,"doi":"10.1038/s41392-025-02252-5","url":"https://doi.org/10.1038/s41392-025-02252-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Manageable grade 3 or 4 treatment-related adverse events developed in 27.3% (12/44) of patients. 6 Similarly, the RATIONALE-312 trial revealed tislelizumab’s clinical benefit, showing enhanced PFS (median 4.7 vs 4.3 months; HR = 0.64, 95% CI 0.52-0.78) and OS outcomes (median 15.5 vs 13.5 months; HR = 0.75, 95% CI 0.61-0.93).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Wallen 2024","year":2024,"doi":"10.3389/fimmu.2024.1413956","url":"https://doi.org/10.3389/fimmu.2024.1413956","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Further, we found younger male patients treated with immunotherapy alone had significantly worse survival compared to male patients ≥65 years, while the addition of chemotherapy reduced this disparity. More than 238,000 new cases of lung cancer were estimated for 2023 in the United States (US), and 85% of cases will be diagnosed as non-small cell lung cancer (NSCLC) ( 1 ).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Hoang 2025","year":2025,"doi":"10.1038/s44319-025-00516-3","url":"https://doi.org/10.1038/s44319-025-00516-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"The muscle mass/body weight was slightly different at steady state, old muscles being 6.1% lighter than young muscles. The cross-sectional area of the regenerating myofibers was decreased at day 7 (-14%) and remained lower at day 28 (-26.3%) post injury in old mice where notably the number of large myofibers was strongly reduced (Figs.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Boudhabhay 2026","year":2026,"doi":"10.1016/j.ekir.2025.103766","url":"https://doi.org/10.1016/j.ekir.2025.103766","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"3.2-2.3, P < 0.0001) and more severe initial AKI (peak creatinine: 360 vs. Relapses occurred more frequently in cluster 3 (38% vs.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_10","claim":"Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, immune, immune and inflammation, longevity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.","citation_support":[],"candidate_sources":[{"study":"Jongsma 2023","year":2023,"doi":"10.1093/ecco-jcc/jjad049","url":"https://doi.org/10.1093/ecco-jcc/jjad049","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Pre- [ n = 86], and 10-14-week post-treatment [ n = 84] sera were collected from patients with moderate-to-severe paediatric CD in the TISKids trial, randomized to FL-IFX [ n = 48; five 5-mg/kg infusions over 22 weeks] or CONV [ n = 43; exclusive enteral nutrition or oral prednisolone]; both groups received azathioprine maintenance. In a large newly diagnosed adult cohort, a five-protein model predicted a subgroup with a high risk for inflammatory bowel disease [IBD] needing treatment escalation [median follow-up, 518 days] 20 ; this model had better accuracy for ulcerative colitis [UC] than for CD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Xie 2025","year":2025,"doi":"10.1038/s41392-025-02252-5","url":"https://doi.org/10.1038/s41392-025-02252-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Manageable grade 3 or 4 treatment-related adverse events developed in 27.3% (12/44) of patients. 6 Similarly, the RATIONALE-312 trial revealed tislelizumab’s clinical benefit, showing enhanced PFS (median 4.7 vs 4.3 months; HR = 0.64, 95% CI 0.52-0.78) and OS outcomes (median 15.5 vs 13.5 months; HR = 0.75, 95% CI 0.61-0.93).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Wallen 2024","year":2024,"doi":"10.3389/fimmu.2024.1413956","url":"https://doi.org/10.3389/fimmu.2024.1413956","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Further, we found younger male patients treated with immunotherapy alone had significantly worse survival compared to male patients ≥65 years, while the addition of chemotherapy reduced this disparity. More than 238,000 new cases of lung cancer were estimated for 2023 in the United States (US), and 85% of cases will be diagnosed as non-small cell lung cancer (NSCLC) ( 1 ).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Hoang 2025","year":2025,"doi":"10.1038/s44319-025-00516-3","url":"https://doi.org/10.1038/s44319-025-00516-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"The muscle mass/body weight was slightly different at steady state, old muscles being 6.1% lighter than young muscles. The cross-sectional area of the regenerating myofibers was decreased at day 7 (-14%) and remained lower at day 28 (-26.3%) post injury in old mice where notably the number of large myofibers was strongly reduced (Figs.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Boudhabhay 2026","year":2026,"doi":"10.1016/j.ekir.2025.103766","url":"https://doi.org/10.1016/j.ekir.2025.103766","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"3.2-2.3, P < 0.0001) and more severe initial AKI (peak creatinine: 360 vs. Relapses occurred more frequently in cluster 3 (38% vs.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_11","claim":"Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.","citation_support":[],"candidate_sources":[{"study":"Jongsma 2023","year":2023,"doi":"10.1093/ecco-jcc/jjad049","url":"https://doi.org/10.1093/ecco-jcc/jjad049","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Pre- [ n = 86], and 10-14-week post-treatment [ n = 84] sera were collected from patients with moderate-to-severe paediatric CD in the TISKids trial, randomized to FL-IFX [ n = 48; five 5-mg/kg infusions over 22 weeks] or CONV [ n = 43; exclusive enteral nutrition or oral prednisolone]; both groups received azathioprine maintenance. In a large newly diagnosed adult cohort, a five-protein model predicted a subgroup with a high risk for inflammatory bowel disease [IBD] needing treatment escalation [median follow-up, 518 days] 20 ; this model had better accuracy for ulcerative colitis [UC] than for CD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Xie 2025","year":2025,"doi":"10.1038/s41392-025-02252-5","url":"https://doi.org/10.1038/s41392-025-02252-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Manageable grade 3 or 4 treatment-related adverse events developed in 27.3% (12/44) of patients. 6 Similarly, the RATIONALE-312 trial revealed tislelizumab’s clinical benefit, showing enhanced PFS (median 4.7 vs 4.3 months; HR = 0.64, 95% CI 0.52-0.78) and OS outcomes (median 15.5 vs 13.5 months; HR = 0.75, 95% CI 0.61-0.93).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Wallen 2024","year":2024,"doi":"10.3389/fimmu.2024.1413956","url":"https://doi.org/10.3389/fimmu.2024.1413956","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Further, we found younger male patients treated with immunotherapy alone had significantly worse survival compared to male patients ≥65 years, while the addition of chemotherapy reduced this disparity. More than 238,000 new cases of lung cancer were estimated for 2023 in the United States (US), and 85% of cases will be diagnosed as non-small cell lung cancer (NSCLC) ( 1 ).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Hoang 2025","year":2025,"doi":"10.1038/s44319-025-00516-3","url":"https://doi.org/10.1038/s44319-025-00516-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"The muscle mass/body weight was slightly different at steady state, old muscles being 6.1% lighter than young muscles. The cross-sectional area of the regenerating myofibers was decreased at day 7 (-14%) and remained lower at day 28 (-26.3%) post injury in old mice where notably the number of large myofibers was strongly reduced (Figs.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Boudhabhay 2026","year":2026,"doi":"10.1016/j.ekir.2025.103766","url":"https://doi.org/10.1016/j.ekir.2025.103766","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"3.2-2.3, P < 0.0001) and more severe initial AKI (peak creatinine: 360 vs. Relapses occurred more frequently in cluster 3 (38% vs.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_12","claim":"Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.","citation_support":[],"candidate_sources":[{"study":"Jongsma 2023","year":2023,"doi":"10.1093/ecco-jcc/jjad049","url":"https://doi.org/10.1093/ecco-jcc/jjad049","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Pre- [ n = 86], and 10-14-week post-treatment [ n = 84] sera were collected from patients with moderate-to-severe paediatric CD in the TISKids trial, randomized to FL-IFX [ n = 48; five 5-mg/kg infusions over 22 weeks] or CONV [ n = 43; exclusive enteral nutrition or oral prednisolone]; both groups received azathioprine maintenance. In a large newly diagnosed adult cohort, a five-protein model predicted a subgroup with a high risk for inflammatory bowel disease [IBD] needing treatment escalation [median follow-up, 518 days] 20 ; this model had better accuracy for ulcerative colitis [UC] than for CD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Xie 2025","year":2025,"doi":"10.1038/s41392-025-02252-5","url":"https://doi.org/10.1038/s41392-025-02252-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Manageable grade 3 or 4 treatment-related adverse events developed in 27.3% (12/44) of patients. 6 Similarly, the RATIONALE-312 trial revealed tislelizumab’s clinical benefit, showing enhanced PFS (median 4.7 vs 4.3 months; HR = 0.64, 95% CI 0.52-0.78) and OS outcomes (median 15.5 vs 13.5 months; HR = 0.75, 95% CI 0.61-0.93).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Wallen 2024","year":2024,"doi":"10.3389/fimmu.2024.1413956","url":"https://doi.org/10.3389/fimmu.2024.1413956","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Further, we found younger male patients treated with immunotherapy alone had significantly worse survival compared to male patients ≥65 years, while the addition of chemotherapy reduced this disparity. More than 238,000 new cases of lung cancer were estimated for 2023 in the United States (US), and 85% of cases will be diagnosed as non-small cell lung cancer (NSCLC) ( 1 ).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Hoang 2025","year":2025,"doi":"10.1038/s44319-025-00516-3","url":"https://doi.org/10.1038/s44319-025-00516-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"The muscle mass/body weight was slightly different at steady state, old muscles being 6.1% lighter than young muscles. The cross-sectional area of the regenerating myofibers was decreased at day 7 (-14%) and remained lower at day 28 (-26.3%) post injury in old mice where notably the number of large myofibers was strongly reduced (Figs.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Boudhabhay 2026","year":2026,"doi":"10.1016/j.ekir.2025.103766","url":"https://doi.org/10.1016/j.ekir.2025.103766","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"3.2-2.3, P < 0.0001) and more severe initial AKI (peak creatinine: 360 vs. Relapses occurred more frequently in cluster 3 (38% vs.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_13","claim":"| Contextual Adjacent Evidence | n=1; claims=2 | no extracted directional signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |","citation_support":[],"candidate_sources":[{"study":"Jongsma 2023","year":2023,"doi":"10.1093/ecco-jcc/jjad049","url":"https://doi.org/10.1093/ecco-jcc/jjad049","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Pre- [ n = 86], and 10-14-week post-treatment [ n = 84] sera were collected from patients with moderate-to-severe paediatric CD in the TISKids trial, randomized to FL-IFX [ n = 48; five 5-mg/kg infusions over 22 weeks] or CONV [ n = 43; exclusive enteral nutrition or oral prednisolone]; both groups received azathioprine maintenance. In a large newly diagnosed adult cohort, a five-protein model predicted a subgroup with a high risk for inflammatory bowel disease [IBD] needing treatment escalation [median follow-up, 518 days] 20 ; this model had better accuracy for ulcerative colitis [UC] than for CD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Xie 2025","year":2025,"doi":"10.1038/s41392-025-02252-5","url":"https://doi.org/10.1038/s41392-025-02252-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Manageable grade 3 or 4 treatment-related adverse events developed in 27.3% (12/44) of patients. 6 Similarly, the RATIONALE-312 trial revealed tislelizumab’s clinical benefit, showing enhanced PFS (median 4.7 vs 4.3 months; HR = 0.64, 95% CI 0.52-0.78) and OS outcomes (median 15.5 vs 13.5 months; HR = 0.75, 95% CI 0.61-0.93).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Wallen 2024","year":2024,"doi":"10.3389/fimmu.2024.1413956","url":"https://doi.org/10.3389/fimmu.2024.1413956","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Further, we found younger male patients treated with immunotherapy alone had significantly worse survival compared to male patients ≥65 years, while the addition of chemotherapy reduced this disparity. More than 238,000 new cases of lung cancer were estimated for 2023 in the United States (US), and 85% of cases will be diagnosed as non-small cell lung cancer (NSCLC) ( 1 ).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Hoang 2025","year":2025,"doi":"10.1038/s44319-025-00516-3","url":"https://doi.org/10.1038/s44319-025-00516-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"The muscle mass/body weight was slightly different at steady state, old muscles being 6.1% lighter than young muscles. The cross-sectional area of the regenerating myofibers was decreased at day 7 (-14%) and remained lower at day 28 (-26.3%) post injury in old mice where notably the number of large myofibers was strongly reduced (Figs.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Boudhabhay 2026","year":2026,"doi":"10.1016/j.ekir.2025.103766","url":"https://doi.org/10.1016/j.ekir.2025.103766","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"3.2-2.3, P < 0.0001) and more severe initial AKI (peak creatinine: 360 vs. Relapses occurred more frequently in cluster 3 (38% vs.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_14","claim":"This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate.","citation_support":[],"candidate_sources":[{"study":"Jongsma 2023","year":2023,"doi":"10.1093/ecco-jcc/jjad049","url":"https://doi.org/10.1093/ecco-jcc/jjad049","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Pre- [ n = 86], and 10-14-week post-treatment [ n = 84] sera were collected from patients with moderate-to-severe paediatric CD in the TISKids trial, randomized to FL-IFX [ n = 48; five 5-mg/kg infusions over 22 weeks] or CONV [ n = 43; exclusive enteral nutrition or oral prednisolone]; both groups received azathioprine maintenance. In a large newly diagnosed adult cohort, a five-protein model predicted a subgroup with a high risk for inflammatory bowel disease [IBD] needing treatment escalation [median follow-up, 518 days] 20 ; this model had better accuracy for ulcerative colitis [UC] than for CD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Xie 2025","year":2025,"doi":"10.1038/s41392-025-02252-5","url":"https://doi.org/10.1038/s41392-025-02252-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Manageable grade 3 or 4 treatment-related adverse events developed in 27.3% (12/44) of patients. 6 Similarly, the RATIONALE-312 trial revealed tislelizumab’s clinical benefit, showing enhanced PFS (median 4.7 vs 4.3 months; HR = 0.64, 95% CI 0.52-0.78) and OS outcomes (median 15.5 vs 13.5 months; HR = 0.75, 95% CI 0.61-0.93).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Wallen 2024","year":2024,"doi":"10.3389/fimmu.2024.1413956","url":"https://doi.org/10.3389/fimmu.2024.1413956","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Further, we found younger male patients treated with immunotherapy alone had significantly worse survival compared to male patients ≥65 years, while the addition of chemotherapy reduced this disparity. More than 238,000 new cases of lung cancer were estimated for 2023 in the United States (US), and 85% of cases will be diagnosed as non-small cell lung cancer (NSCLC) ( 1 ).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Hoang 2025","year":2025,"doi":"10.1038/s44319-025-00516-3","url":"https://doi.org/10.1038/s44319-025-00516-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"The muscle mass/body weight was slightly different at steady state, old muscles being 6.1% lighter than young muscles. The cross-sectional area of the regenerating myofibers was decreased at day 7 (-14%) and remained lower at day 28 (-26.3%) post injury in old mice where notably the number of large myofibers was strongly reduced (Figs.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Boudhabhay 2026","year":2026,"doi":"10.1016/j.ekir.2025.103766","url":"https://doi.org/10.1016/j.ekir.2025.103766","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"3.2-2.3, P < 0.0001) and more severe initial AKI (peak creatinine: 360 vs. Relapses occurred more frequently in cluster 3 (38% vs.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_15","claim":"27 included sources were assigned to this outcome class. Directional coding: null=27. Directness coding: indirect=25, mechanistic=2.","citation_support":[],"candidate_sources":[{"study":"Jongsma 2023","year":2023,"doi":"10.1093/ecco-jcc/jjad049","url":"https://doi.org/10.1093/ecco-jcc/jjad049","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Pre- [ n = 86], and 10-14-week post-treatment [ n = 84] sera were collected from patients with moderate-to-severe paediatric CD in the TISKids trial, randomized to FL-IFX [ n = 48; five 5-mg/kg infusions over 22 weeks] or CONV [ n = 43; exclusive enteral nutrition or oral prednisolone]; both groups received azathioprine maintenance. In a large newly diagnosed adult cohort, a five-protein model predicted a subgroup with a high risk for inflammatory bowel disease [IBD] needing treatment escalation [median follow-up, 518 days] 20 ; this model had better accuracy for ulcerative colitis [UC] than for CD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Xie 2025","year":2025,"doi":"10.1038/s41392-025-02252-5","url":"https://doi.org/10.1038/s41392-025-02252-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Manageable grade 3 or 4 treatment-related adverse events developed in 27.3% (12/44) of patients. 6 Similarly, the RATIONALE-312 trial revealed tislelizumab’s clinical benefit, showing enhanced PFS (median 4.7 vs 4.3 months; HR = 0.64, 95% CI 0.52-0.78) and OS outcomes (median 15.5 vs 13.5 months; HR = 0.75, 95% CI 0.61-0.93).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Wallen 2024","year":2024,"doi":"10.3389/fimmu.2024.1413956","url":"https://doi.org/10.3389/fimmu.2024.1413956","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Further, we found younger male patients treated with immunotherapy alone had significantly worse survival compared to male patients ≥65 years, while the addition of chemotherapy reduced this disparity. More than 238,000 new cases of lung cancer were estimated for 2023 in the United States (US), and 85% of cases will be diagnosed as non-small cell lung cancer (NSCLC) ( 1 ).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Hoang 2025","year":2025,"doi":"10.1038/s44319-025-00516-3","url":"https://doi.org/10.1038/s44319-025-00516-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"The muscle mass/body weight was slightly different at steady state, old muscles being 6.1% lighter than young muscles. The cross-sectional area of the regenerating myofibers was decreased at day 7 (-14%) and remained lower at day 28 (-26.3%) post injury in old mice where notably the number of large myofibers was strongly reduced (Figs.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Boudhabhay 2026","year":2026,"doi":"10.1016/j.ekir.2025.103766","url":"https://doi.org/10.1016/j.ekir.2025.103766","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"3.2-2.3, P < 0.0001) and more severe initial AKI (peak creatinine: 360 vs. Relapses occurred more frequently in cluster 3 (38% vs.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_16","claim":"8 included sources were assigned to this outcome class. Directional coding: null=8. Directness coding: indirect=7, mechanistic=1.","citation_support":[],"candidate_sources":[{"study":"Jongsma 2023","year":2023,"doi":"10.1093/ecco-jcc/jjad049","url":"https://doi.org/10.1093/ecco-jcc/jjad049","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Pre- [ n = 86], and 10-14-week post-treatment [ n = 84] sera were collected from patients with moderate-to-severe paediatric CD in the TISKids trial, randomized to FL-IFX [ n = 48; five 5-mg/kg infusions over 22 weeks] or CONV [ n = 43; exclusive enteral nutrition or oral prednisolone]; both groups received azathioprine maintenance. In a large newly diagnosed adult cohort, a five-protein model predicted a subgroup with a high risk for inflammatory bowel disease [IBD] needing treatment escalation [median follow-up, 518 days] 20 ; this model had better accuracy for ulcerative colitis [UC] than for CD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Xie 2025","year":2025,"doi":"10.1038/s41392-025-02252-5","url":"https://doi.org/10.1038/s41392-025-02252-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Manageable grade 3 or 4 treatment-related adverse events developed in 27.3% (12/44) of patients. 6 Similarly, the RATIONALE-312 trial revealed tislelizumab’s clinical benefit, showing enhanced PFS (median 4.7 vs 4.3 months; HR = 0.64, 95% CI 0.52-0.78) and OS outcomes (median 15.5 vs 13.5 months; HR = 0.75, 95% CI 0.61-0.93).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Wallen 2024","year":2024,"doi":"10.3389/fimmu.2024.1413956","url":"https://doi.org/10.3389/fimmu.2024.1413956","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Further, we found younger male patients treated with immunotherapy alone had significantly worse survival compared to male patients ≥65 years, while the addition of chemotherapy reduced this disparity. More than 238,000 new cases of lung cancer were estimated for 2023 in the United States (US), and 85% of cases will be diagnosed as non-small cell lung cancer (NSCLC) ( 1 ).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Hoang 2025","year":2025,"doi":"10.1038/s44319-025-00516-3","url":"https://doi.org/10.1038/s44319-025-00516-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"The muscle mass/body weight was slightly different at steady state, old muscles being 6.1% lighter than young muscles. The cross-sectional area of the regenerating myofibers was decreased at day 7 (-14%) and remained lower at day 28 (-26.3%) post injury in old mice where notably the number of large myofibers was strongly reduced (Figs.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Boudhabhay 2026","year":2026,"doi":"10.1016/j.ekir.2025.103766","url":"https://doi.org/10.1016/j.ekir.2025.103766","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"3.2-2.3, P < 0.0001) and more severe initial AKI (peak creatinine: 360 vs. Relapses occurred more frequently in cluster 3 (38% vs.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_17","claim":"3 included sources were assigned to this outcome class. Directional coding: null=3. Directness coding: indirect=3.","citation_support":[],"candidate_sources":[{"study":"Jongsma 2023","year":2023,"doi":"10.1093/ecco-jcc/jjad049","url":"https://doi.org/10.1093/ecco-jcc/jjad049","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Pre- [ n = 86], and 10-14-week post-treatment [ n = 84] sera were collected from patients with moderate-to-severe paediatric CD in the TISKids trial, randomized to FL-IFX [ n = 48; five 5-mg/kg infusions over 22 weeks] or CONV [ n = 43; exclusive enteral nutrition or oral prednisolone]; both groups received azathioprine maintenance. In a large newly diagnosed adult cohort, a five-protein model predicted a subgroup with a high risk for inflammatory bowel disease [IBD] needing treatment escalation [median follow-up, 518 days] 20 ; this model had better accuracy for ulcerative colitis [UC] than for CD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Xie 2025","year":2025,"doi":"10.1038/s41392-025-02252-5","url":"https://doi.org/10.1038/s41392-025-02252-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Manageable grade 3 or 4 treatment-related adverse events developed in 27.3% (12/44) of patients. 6 Similarly, the RATIONALE-312 trial revealed tislelizumab’s clinical benefit, showing enhanced PFS (median 4.7 vs 4.3 months; HR = 0.64, 95% CI 0.52-0.78) and OS outcomes (median 15.5 vs 13.5 months; HR = 0.75, 95% CI 0.61-0.93).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Wallen 2024","year":2024,"doi":"10.3389/fimmu.2024.1413956","url":"https://doi.org/10.3389/fimmu.2024.1413956","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Further, we found younger male patients treated with immunotherapy alone had significantly worse survival compared to male patients ≥65 years, while the addition of chemotherapy reduced this disparity. More than 238,000 new cases of lung cancer were estimated for 2023 in the United States (US), and 85% of cases will be diagnosed as non-small cell lung cancer (NSCLC) ( 1 ).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Hoang 2025","year":2025,"doi":"10.1038/s44319-025-00516-3","url":"https://doi.org/10.1038/s44319-025-00516-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"The muscle mass/body weight was slightly different at steady state, old muscles being 6.1% lighter than young muscles. The cross-sectional area of the regenerating myofibers was decreased at day 7 (-14%) and remained lower at day 28 (-26.3%) post injury in old mice where notably the number of large myofibers was strongly reduced (Figs.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Boudhabhay 2026","year":2026,"doi":"10.1016/j.ekir.2025.103766","url":"https://doi.org/10.1016/j.ekir.2025.103766","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"3.2-2.3, P < 0.0001) and more severe initial AKI (peak creatinine: 360 vs. Relapses occurred more frequently in cluster 3 (38% vs.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_18","claim":"1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.","citation_support":[],"candidate_sources":[{"study":"Jongsma 2023","year":2023,"doi":"10.1093/ecco-jcc/jjad049","url":"https://doi.org/10.1093/ecco-jcc/jjad049","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Pre- [ n = 86], and 10-14-week post-treatment [ n = 84] sera were collected from patients with moderate-to-severe paediatric CD in the TISKids trial, randomized to FL-IFX [ n = 48; five 5-mg/kg infusions over 22 weeks] or CONV [ n = 43; exclusive enteral nutrition or oral prednisolone]; both groups received azathioprine maintenance. In a large newly diagnosed adult cohort, a five-protein model predicted a subgroup with a high risk for inflammatory bowel disease [IBD] needing treatment escalation [median follow-up, 518 days] 20 ; this model had better accuracy for ulcerative colitis [UC] than for CD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Xie 2025","year":2025,"doi":"10.1038/s41392-025-02252-5","url":"https://doi.org/10.1038/s41392-025-02252-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Manageable grade 3 or 4 treatment-related adverse events developed in 27.3% (12/44) of patients. 6 Similarly, the RATIONALE-312 trial revealed tislelizumab’s clinical benefit, showing enhanced PFS (median 4.7 vs 4.3 months; HR = 0.64, 95% CI 0.52-0.78) and OS outcomes (median 15.5 vs 13.5 months; HR = 0.75, 95% CI 0.61-0.93).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Wallen 2024","year":2024,"doi":"10.3389/fimmu.2024.1413956","url":"https://doi.org/10.3389/fimmu.2024.1413956","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Further, we found younger male patients treated with immunotherapy alone had significantly worse survival compared to male patients ≥65 years, while the addition of chemotherapy reduced this disparity. More than 238,000 new cases of lung cancer were estimated for 2023 in the United States (US), and 85% of cases will be diagnosed as non-small cell lung cancer (NSCLC) ( 1 ).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Hoang 2025","year":2025,"doi":"10.1038/s44319-025-00516-3","url":"https://doi.org/10.1038/s44319-025-00516-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"The muscle mass/body weight was slightly different at steady state, old muscles being 6.1% lighter than young muscles. The cross-sectional area of the regenerating myofibers was decreased at day 7 (-14%) and remained lower at day 28 (-26.3%) post injury in old mice where notably the number of large myofibers was strongly reduced (Figs.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Boudhabhay 2026","year":2026,"doi":"10.1016/j.ekir.2025.103766","url":"https://doi.org/10.1016/j.ekir.2025.103766","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"3.2-2.3, P < 0.0001) and more severe initial AKI (peak creatinine: 360 vs. Relapses occurred more frequently in cluster 3 (38% vs.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_19","claim":"1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.","citation_support":[],"candidate_sources":[{"study":"Jongsma 2023","year":2023,"doi":"10.1093/ecco-jcc/jjad049","url":"https://doi.org/10.1093/ecco-jcc/jjad049","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Pre- [ n = 86], and 10-14-week post-treatment [ n = 84] sera were collected from patients with moderate-to-severe paediatric CD in the TISKids trial, randomized to FL-IFX [ n = 48; five 5-mg/kg infusions over 22 weeks] or CONV [ n = 43; exclusive enteral nutrition or oral prednisolone]; both groups received azathioprine maintenance. In a large newly diagnosed adult cohort, a five-protein model predicted a subgroup with a high risk for inflammatory bowel disease [IBD] needing treatment escalation [median follow-up, 518 days] 20 ; this model had better accuracy for ulcerative colitis [UC] than for CD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Xie 2025","year":2025,"doi":"10.1038/s41392-025-02252-5","url":"https://doi.org/10.1038/s41392-025-02252-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Manageable grade 3 or 4 treatment-related adverse events developed in 27.3% (12/44) of patients. 6 Similarly, the RATIONALE-312 trial revealed tislelizumab’s clinical benefit, showing enhanced PFS (median 4.7 vs 4.3 months; HR = 0.64, 95% CI 0.52-0.78) and OS outcomes (median 15.5 vs 13.5 months; HR = 0.75, 95% CI 0.61-0.93).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Wallen 2024","year":2024,"doi":"10.3389/fimmu.2024.1413956","url":"https://doi.org/10.3389/fimmu.2024.1413956","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Further, we found younger male patients treated with immunotherapy alone had significantly worse survival compared to male patients ≥65 years, while the addition of chemotherapy reduced this disparity. More than 238,000 new cases of lung cancer were estimated for 2023 in the United States (US), and 85% of cases will be diagnosed as non-small cell lung cancer (NSCLC) ( 1 ).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Hoang 2025","year":2025,"doi":"10.1038/s44319-025-00516-3","url":"https://doi.org/10.1038/s44319-025-00516-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"The muscle mass/body weight was slightly different at steady state, old muscles being 6.1% lighter than young muscles. The cross-sectional area of the regenerating myofibers was decreased at day 7 (-14%) and remained lower at day 28 (-26.3%) post injury in old mice where notably the number of large myofibers was strongly reduced (Figs.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Boudhabhay 2026","year":2026,"doi":"10.1016/j.ekir.2025.103766","url":"https://doi.org/10.1016/j.ekir.2025.103766","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"3.2-2.3, P < 0.0001) and more severe initial AKI (peak creatinine: 360 vs. Relapses occurred more frequently in cluster 3 (38% vs.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_20","claim":"1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.","citation_support":[],"candidate_sources":[{"study":"Jongsma 2023","year":2023,"doi":"10.1093/ecco-jcc/jjad049","url":"https://doi.org/10.1093/ecco-jcc/jjad049","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Pre- [ n = 86], and 10-14-week post-treatment [ n = 84] sera were collected from patients with moderate-to-severe paediatric CD in the TISKids trial, randomized to FL-IFX [ n = 48; five 5-mg/kg infusions over 22 weeks] or CONV [ n = 43; exclusive enteral nutrition or oral prednisolone]; both groups received azathioprine maintenance. In a large newly diagnosed adult cohort, a five-protein model predicted a subgroup with a high risk for inflammatory bowel disease [IBD] needing treatment escalation [median follow-up, 518 days] 20 ; this model had better accuracy for ulcerative colitis [UC] than for CD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Xie 2025","year":2025,"doi":"10.1038/s41392-025-02252-5","url":"https://doi.org/10.1038/s41392-025-02252-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Manageable grade 3 or 4 treatment-related adverse events developed in 27.3% (12/44) of patients. 6 Similarly, the RATIONALE-312 trial revealed tislelizumab’s clinical benefit, showing enhanced PFS (median 4.7 vs 4.3 months; HR = 0.64, 95% CI 0.52-0.78) and OS outcomes (median 15.5 vs 13.5 months; HR = 0.75, 95% CI 0.61-0.93).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Wallen 2024","year":2024,"doi":"10.3389/fimmu.2024.1413956","url":"https://doi.org/10.3389/fimmu.2024.1413956","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Further, we found younger male patients treated with immunotherapy alone had significantly worse survival compared to male patients ≥65 years, while the addition of chemotherapy reduced this disparity. More than 238,000 new cases of lung cancer were estimated for 2023 in the United States (US), and 85% of cases will be diagnosed as non-small cell lung cancer (NSCLC) ( 1 ).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Hoang 2025","year":2025,"doi":"10.1038/s44319-025-00516-3","url":"https://doi.org/10.1038/s44319-025-00516-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"The muscle mass/body weight was slightly different at steady state, old muscles being 6.1% lighter than young muscles. The cross-sectional area of the regenerating myofibers was decreased at day 7 (-14%) and remained lower at day 28 (-26.3%) post injury in old mice where notably the number of large myofibers was strongly reduced (Figs.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Boudhabhay 2026","year":2026,"doi":"10.1016/j.ekir.2025.103766","url":"https://doi.org/10.1016/j.ekir.2025.103766","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"3.2-2.3, P < 0.0001) and more severe initial AKI (peak creatinine: 360 vs. Relapses occurred more frequently in cluster 3 (38% vs.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_21","claim":"Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.","citation_support":[],"candidate_sources":[{"study":"Jongsma 2023","year":2023,"doi":"10.1093/ecco-jcc/jjad049","url":"https://doi.org/10.1093/ecco-jcc/jjad049","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Pre- [ n = 86], and 10-14-week post-treatment [ n = 84] sera were collected from patients with moderate-to-severe paediatric CD in the TISKids trial, randomized to FL-IFX [ n = 48; five 5-mg/kg infusions over 22 weeks] or CONV [ n = 43; exclusive enteral nutrition or oral prednisolone]; both groups received azathioprine maintenance. In a large newly diagnosed adult cohort, a five-protein model predicted a subgroup with a high risk for inflammatory bowel disease [IBD] needing treatment escalation [median follow-up, 518 days] 20 ; this model had better accuracy for ulcerative colitis [UC] than for CD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Xie 2025","year":2025,"doi":"10.1038/s41392-025-02252-5","url":"https://doi.org/10.1038/s41392-025-02252-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Manageable grade 3 or 4 treatment-related adverse events developed in 27.3% (12/44) of patients. 6 Similarly, the RATIONALE-312 trial revealed tislelizumab’s clinical benefit, showing enhanced PFS (median 4.7 vs 4.3 months; HR = 0.64, 95% CI 0.52-0.78) and OS outcomes (median 15.5 vs 13.5 months; HR = 0.75, 95% CI 0.61-0.93).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Wallen 2024","year":2024,"doi":"10.3389/fimmu.2024.1413956","url":"https://doi.org/10.3389/fimmu.2024.1413956","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Further, we found younger male patients treated with immunotherapy alone had significantly worse survival compared to male patients ≥65 years, while the addition of chemotherapy reduced this disparity. More than 238,000 new cases of lung cancer were estimated for 2023 in the United States (US), and 85% of cases will be diagnosed as non-small cell lung cancer (NSCLC) ( 1 ).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Hoang 2025","year":2025,"doi":"10.1038/s44319-025-00516-3","url":"https://doi.org/10.1038/s44319-025-00516-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"The muscle mass/body weight was slightly different at steady state, old muscles being 6.1% lighter than young muscles. The cross-sectional area of the regenerating myofibers was decreased at day 7 (-14%) and remained lower at day 28 (-26.3%) post injury in old mice where notably the number of large myofibers was strongly reduced (Figs.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Boudhabhay 2026","year":2026,"doi":"10.1016/j.ekir.2025.103766","url":"https://doi.org/10.1016/j.ekir.2025.103766","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"3.2-2.3, P < 0.0001) and more severe initial AKI (peak creatinine: 360 vs. Relapses occurred more frequently in cluster 3 (38% vs.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_22","claim":"A primary limitation is the absence of large, prospective, randomized controlled trials designed to test immune aging interventions against hard clinical endpoints. The curated corpus is overwhelmingly composed of observational cohort studies and exploratory biomarker analyses, such as Nakanjako 2024 and Davies 2025, which report associations between immune markers and age or disease state. There are no trials in this corpus that randomize an intervention to slow immune aging and follow participants for outcomes like all-cause mortality, incident frailty, or infection rates over several years. Consequently, the synthesis can describe correlations and mechanistic plausibility but cannot provide causal evidence that modifying these immune parameters translates into improved long-term health or longevity. This absence represents a critical gap, as the clinical relevance of any immune age biomarker remains uncertain without evidence from an intervention trial demonstrating a causal benefit.","citation_support":[],"candidate_sources":[{"study":"Jongsma 2023","year":2023,"doi":"10.1093/ecco-jcc/jjad049","url":"https://doi.org/10.1093/ecco-jcc/jjad049","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Pre- [ n = 86], and 10-14-week post-treatment [ n = 84] sera were collected from patients with moderate-to-severe paediatric CD in the TISKids trial, randomized to FL-IFX [ n = 48; five 5-mg/kg infusions over 22 weeks] or CONV [ n = 43; exclusive enteral nutrition or oral prednisolone]; both groups received azathioprine maintenance. In a large newly diagnosed adult cohort, a five-protein model predicted a subgroup with a high risk for inflammatory bowel disease [IBD] needing treatment escalation [median follow-up, 518 days] 20 ; this model had better accuracy for ulcerative colitis [UC] than for CD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Xie 2025","year":2025,"doi":"10.1038/s41392-025-02252-5","url":"https://doi.org/10.1038/s41392-025-02252-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Manageable grade 3 or 4 treatment-related adverse events developed in 27.3% (12/44) of patients. 6 Similarly, the RATIONALE-312 trial revealed tislelizumab’s clinical benefit, showing enhanced PFS (median 4.7 vs 4.3 months; HR = 0.64, 95% CI 0.52-0.78) and OS outcomes (median 15.5 vs 13.5 months; HR = 0.75, 95% CI 0.61-0.93).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Wallen 2024","year":2024,"doi":"10.3389/fimmu.2024.1413956","url":"https://doi.org/10.3389/fimmu.2024.1413956","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Further, we found younger male patients treated with immunotherapy alone had significantly worse survival compared to male patients ≥65 years, while the addition of chemotherapy reduced this disparity. More than 238,000 new cases of lung cancer were estimated for 2023 in the United States (US), and 85% of cases will be diagnosed as non-small cell lung cancer (NSCLC) ( 1 ).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Hoang 2025","year":2025,"doi":"10.1038/s44319-025-00516-3","url":"https://doi.org/10.1038/s44319-025-00516-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"The muscle mass/body weight was slightly different at steady state, old muscles being 6.1% lighter than young muscles. The cross-sectional area of the regenerating myofibers was decreased at day 7 (-14%) and remained lower at day 28 (-26.3%) post injury in old mice where notably the number of large myofibers was strongly reduced (Figs.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Boudhabhay 2026","year":2026,"doi":"10.1016/j.ekir.2025.103766","url":"https://doi.org/10.1016/j.ekir.2025.103766","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"3.2-2.3, P < 0.0001) and more severe initial AKI (peak creatinine: 360 vs. Relapses occurred more frequently in cluster 3 (38% vs.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_23","claim":"The evidence base is also limited by its heavy reliance on findings from single studies for specific outcomes, which precludes internal replication within the corpus. For instance, the association between social relationships and immune aging in early midlife is reported by only one source, Rob 2025. Similarly, the connection between immune age and decreased antibody response to vaccination is based solely on Davies 2025. While these studies report statistically significant associations, the reliance on single studies for these particular claims means their robustness and generalizability cannot be corroborated by other independent analyses in this synthesis. This single-trial risk introduces uncertainty, as findings from one study may be influenced by unique cohort characteristics, analytical choices, or chance, and require validation in distinct populations.","citation_support":[],"candidate_sources":[{"study":"Jongsma 2023","year":2023,"doi":"10.1093/ecco-jcc/jjad049","url":"https://doi.org/10.1093/ecco-jcc/jjad049","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Pre- [ n = 86], and 10-14-week post-treatment [ n = 84] sera were collected from patients with moderate-to-severe paediatric CD in the TISKids trial, randomized to FL-IFX [ n = 48; five 5-mg/kg infusions over 22 weeks] or CONV [ n = 43; exclusive enteral nutrition or oral prednisolone]; both groups received azathioprine maintenance. In a large newly diagnosed adult cohort, a five-protein model predicted a subgroup with a high risk for inflammatory bowel disease [IBD] needing treatment escalation [median follow-up, 518 days] 20 ; this model had better accuracy for ulcerative colitis [UC] than for CD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Xie 2025","year":2025,"doi":"10.1038/s41392-025-02252-5","url":"https://doi.org/10.1038/s41392-025-02252-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Manageable grade 3 or 4 treatment-related adverse events developed in 27.3% (12/44) of patients. 6 Similarly, the RATIONALE-312 trial revealed tislelizumab’s clinical benefit, showing enhanced PFS (median 4.7 vs 4.3 months; HR = 0.64, 95% CI 0.52-0.78) and OS outcomes (median 15.5 vs 13.5 months; HR = 0.75, 95% CI 0.61-0.93).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Wallen 2024","year":2024,"doi":"10.3389/fimmu.2024.1413956","url":"https://doi.org/10.3389/fimmu.2024.1413956","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Further, we found younger male patients treated with immunotherapy alone had significantly worse survival compared to male patients ≥65 years, while the addition of chemotherapy reduced this disparity. More than 238,000 new cases of lung cancer were estimated for 2023 in the United States (US), and 85% of cases will be diagnosed as non-small cell lung cancer (NSCLC) ( 1 ).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Hoang 2025","year":2025,"doi":"10.1038/s44319-025-00516-3","url":"https://doi.org/10.1038/s44319-025-00516-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"The muscle mass/body weight was slightly different at steady state, old muscles being 6.1% lighter than young muscles. The cross-sectional area of the regenerating myofibers was decreased at day 7 (-14%) and remained lower at day 28 (-26.3%) post injury in old mice where notably the number of large myofibers was strongly reduced (Figs.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Boudhabhay 2026","year":2026,"doi":"10.1016/j.ekir.2025.103766","url":"https://doi.org/10.1016/j.ekir.2025.103766","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"3.2-2.3, P < 0.0001) and more severe initial AKI (peak creatinine: 360 vs. Relapses occurred more frequently in cluster 3 (38% vs.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_24","claim":"Finally, the corpus primarily characterizes immune aging through cellular and molecular profiling endpoints, with a notable scarcity of evidence linking these markers to clinically relevant functional outcomes. Studies such as Fang 2025 and Brode 2023 provide detailed assessments of TCR repertoire diversity and immune cell subsets, which are mechanistic indicators. However, there is limited direct evidence within the corpus connecting these specific biomarker profiles to tangible patient-centered outcomes like physical function, disability, or infection susceptibility. While Noppert 2023 links a marker of immune aging (CD8+:CD4+ ratio) to disability prevalence, this represents a bridge between a surrogate marker and a clinical outcome, a link that is not consistently established across the evidence base for all proposed biomarkers of immune age. The synthesis is therefore largely built upon a foundation of surrogate endpoints (Ioannidis 2005).","citation_support":[],"candidate_sources":[{"study":"Jongsma 2023","year":2023,"doi":"10.1093/ecco-jcc/jjad049","url":"https://doi.org/10.1093/ecco-jcc/jjad049","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Pre- [ n = 86], and 10-14-week post-treatment [ n = 84] sera were collected from patients with moderate-to-severe paediatric CD in the TISKids trial, randomized to FL-IFX [ n = 48; five 5-mg/kg infusions over 22 weeks] or CONV [ n = 43; exclusive enteral nutrition or oral prednisolone]; both groups received azathioprine maintenance. In a large newly diagnosed adult cohort, a five-protein model predicted a subgroup with a high risk for inflammatory bowel disease [IBD] needing treatment escalation [median follow-up, 518 days] 20 ; this model had better accuracy for ulcerative colitis [UC] than for CD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Xie 2025","year":2025,"doi":"10.1038/s41392-025-02252-5","url":"https://doi.org/10.1038/s41392-025-02252-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Manageable grade 3 or 4 treatment-related adverse events developed in 27.3% (12/44) of patients. 6 Similarly, the RATIONALE-312 trial revealed tislelizumab’s clinical benefit, showing enhanced PFS (median 4.7 vs 4.3 months; HR = 0.64, 95% CI 0.52-0.78) and OS outcomes (median 15.5 vs 13.5 months; HR = 0.75, 95% CI 0.61-0.93).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Wallen 2024","year":2024,"doi":"10.3389/fimmu.2024.1413956","url":"https://doi.org/10.3389/fimmu.2024.1413956","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Further, we found younger male patients treated with immunotherapy alone had significantly worse survival compared to male patients ≥65 years, while the addition of chemotherapy reduced this disparity. More than 238,000 new cases of lung cancer were estimated for 2023 in the United States (US), and 85% of cases will be diagnosed as non-small cell lung cancer (NSCLC) ( 1 ).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Hoang 2025","year":2025,"doi":"10.1038/s44319-025-00516-3","url":"https://doi.org/10.1038/s44319-025-00516-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"The muscle mass/body weight was slightly different at steady state, old muscles being 6.1% lighter than young muscles. The cross-sectional area of the regenerating myofibers was decreased at day 7 (-14%) and remained lower at day 28 (-26.3%) post injury in old mice where notably the number of large myofibers was strongly reduced (Figs.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Boudhabhay 2026","year":2026,"doi":"10.1016/j.ekir.2025.103766","url":"https://doi.org/10.1016/j.ekir.2025.103766","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"3.2-2.3, P < 0.0001) and more severe initial AKI (peak creatinine: 360 vs. Relapses occurred more frequently in cluster 3 (38% vs.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_25","claim":"For immune age, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus may support immune age as a general health or lifestyle intervention where otherwise indicated, but does not justify marketing it as a standalone geroprotective or anti-aging intervention with proven hard-longevity effects. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.","citation_support":[],"candidate_sources":[{"study":"Jongsma 2023","year":2023,"doi":"10.1093/ecco-jcc/jjad049","url":"https://doi.org/10.1093/ecco-jcc/jjad049","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Pre- [ n = 86], and 10-14-week post-treatment [ n = 84] sera were collected from patients with moderate-to-severe paediatric CD in the TISKids trial, randomized to FL-IFX [ n = 48; five 5-mg/kg infusions over 22 weeks] or CONV [ n = 43; exclusive enteral nutrition or oral prednisolone]; both groups received azathioprine maintenance. In a large newly diagnosed adult cohort, a five-protein model predicted a subgroup with a high risk for inflammatory bowel disease [IBD] needing treatment escalation [median follow-up, 518 days] 20 ; this model had better accuracy for ulcerative colitis [UC] than for CD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Xie 2025","year":2025,"doi":"10.1038/s41392-025-02252-5","url":"https://doi.org/10.1038/s41392-025-02252-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Manageable grade 3 or 4 treatment-related adverse events developed in 27.3% (12/44) of patients. 6 Similarly, the RATIONALE-312 trial revealed tislelizumab’s clinical benefit, showing enhanced PFS (median 4.7 vs 4.3 months; HR = 0.64, 95% CI 0.52-0.78) and OS outcomes (median 15.5 vs 13.5 months; HR = 0.75, 95% CI 0.61-0.93).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Wallen 2024","year":2024,"doi":"10.3389/fimmu.2024.1413956","url":"https://doi.org/10.3389/fimmu.2024.1413956","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Further, we found younger male patients treated with immunotherapy alone had significantly worse survival compared to male patients ≥65 years, while the addition of chemotherapy reduced this disparity. More than 238,000 new cases of lung cancer were estimated for 2023 in the United States (US), and 85% of cases will be diagnosed as non-small cell lung cancer (NSCLC) ( 1 ).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Hoang 2025","year":2025,"doi":"10.1038/s44319-025-00516-3","url":"https://doi.org/10.1038/s44319-025-00516-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"The muscle mass/body weight was slightly different at steady state, old muscles being 6.1% lighter than young muscles. The cross-sectional area of the regenerating myofibers was decreased at day 7 (-14%) and remained lower at day 28 (-26.3%) post injury in old mice where notably the number of large myofibers was strongly reduced (Figs.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Boudhabhay 2026","year":2026,"doi":"10.1016/j.ekir.2025.103766","url":"https://doi.org/10.1016/j.ekir.2025.103766","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"3.2-2.3, P < 0.0001) and more severe initial AKI (peak creatinine: 360 vs. Relapses occurred more frequently in cluster 3 (38% vs.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_26","claim":"This synthesis maps 41 included sources on Immune age across 6 outcome classes and 382 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.","citation_support":[],"candidate_sources":[{"study":"Jongsma 2023","year":2023,"doi":"10.1093/ecco-jcc/jjad049","url":"https://doi.org/10.1093/ecco-jcc/jjad049","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Pre- [ n = 86], and 10-14-week post-treatment [ n = 84] sera were collected from patients with moderate-to-severe paediatric CD in the TISKids trial, randomized to FL-IFX [ n = 48; five 5-mg/kg infusions over 22 weeks] or CONV [ n = 43; exclusive enteral nutrition or oral prednisolone]; both groups received azathioprine maintenance. In a large newly diagnosed adult cohort, a five-protein model predicted a subgroup with a high risk for inflammatory bowel disease [IBD] needing treatment escalation [median follow-up, 518 days] 20 ; this model had better accuracy for ulcerative colitis [UC] than for CD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Xie 2025","year":2025,"doi":"10.1038/s41392-025-02252-5","url":"https://doi.org/10.1038/s41392-025-02252-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Manageable grade 3 or 4 treatment-related adverse events developed in 27.3% (12/44) of patients. 6 Similarly, the RATIONALE-312 trial revealed tislelizumab’s clinical benefit, showing enhanced PFS (median 4.7 vs 4.3 months; HR = 0.64, 95% CI 0.52-0.78) and OS outcomes (median 15.5 vs 13.5 months; HR = 0.75, 95% CI 0.61-0.93).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Wallen 2024","year":2024,"doi":"10.3389/fimmu.2024.1413956","url":"https://doi.org/10.3389/fimmu.2024.1413956","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Further, we found younger male patients treated with immunotherapy alone had significantly worse survival compared to male patients ≥65 years, while the addition of chemotherapy reduced this disparity. More than 238,000 new cases of lung cancer were estimated for 2023 in the United States (US), and 85% of cases will be diagnosed as non-small cell lung cancer (NSCLC) ( 1 ).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Hoang 2025","year":2025,"doi":"10.1038/s44319-025-00516-3","url":"https://doi.org/10.1038/s44319-025-00516-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"The muscle mass/body weight was slightly different at steady state, old muscles being 6.1% lighter than young muscles. The cross-sectional area of the regenerating myofibers was decreased at day 7 (-14%) and remained lower at day 28 (-26.3%) post injury in old mice where notably the number of large myofibers was strongly reduced (Figs.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Boudhabhay 2026","year":2026,"doi":"10.1016/j.ekir.2025.103766","url":"https://doi.org/10.1016/j.ekir.2025.103766","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"3.2-2.3, P < 0.0001) and more severe initial AKI (peak creatinine: 360 vs. Relapses occurred more frequently in cluster 3 (38% vs.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_27","claim":"Across 41 curated reference papers, the evidence base for Immune age shows a context-dependent profile. Null findings dominate: immune inflammation, immune. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Immune age anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.","citation_support":[],"candidate_sources":[{"study":"Jongsma 2023","year":2023,"doi":"10.1093/ecco-jcc/jjad049","url":"https://doi.org/10.1093/ecco-jcc/jjad049","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Pre- [ n = 86], and 10-14-week post-treatment [ n = 84] sera were collected from patients with moderate-to-severe paediatric CD in the TISKids trial, randomized to FL-IFX [ n = 48; five 5-mg/kg infusions over 22 weeks] or CONV [ n = 43; exclusive enteral nutrition or oral prednisolone]; both groups received azathioprine maintenance. In a large newly diagnosed adult cohort, a five-protein model predicted a subgroup with a high risk for inflammatory bowel disease [IBD] needing treatment escalation [median follow-up, 518 days] 20 ; this model had better accuracy for ulcerative colitis [UC] than for CD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Xie 2025","year":2025,"doi":"10.1038/s41392-025-02252-5","url":"https://doi.org/10.1038/s41392-025-02252-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Manageable grade 3 or 4 treatment-related adverse events developed in 27.3% (12/44) of patients. 6 Similarly, the RATIONALE-312 trial revealed tislelizumab’s clinical benefit, showing enhanced PFS (median 4.7 vs 4.3 months; HR = 0.64, 95% CI 0.52-0.78) and OS outcomes (median 15.5 vs 13.5 months; HR = 0.75, 95% CI 0.61-0.93).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Wallen 2024","year":2024,"doi":"10.3389/fimmu.2024.1413956","url":"https://doi.org/10.3389/fimmu.2024.1413956","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Further, we found younger male patients treated with immunotherapy alone had significantly worse survival compared to male patients ≥65 years, while the addition of chemotherapy reduced this disparity. More than 238,000 new cases of lung cancer were estimated for 2023 in the United States (US), and 85% of cases will be diagnosed as non-small cell lung cancer (NSCLC) ( 1 ).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Hoang 2025","year":2025,"doi":"10.1038/s44319-025-00516-3","url":"https://doi.org/10.1038/s44319-025-00516-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"The muscle mass/body weight was slightly different at steady state, old muscles being 6.1% lighter than young muscles. The cross-sectional area of the regenerating myofibers was decreased at day 7 (-14%) and remained lower at day 28 (-26.3%) post injury in old mice where notably the number of large myofibers was strongly reduced (Figs.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Boudhabhay 2026","year":2026,"doi":"10.1016/j.ekir.2025.103766","url":"https://doi.org/10.1016/j.ekir.2025.103766","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"3.2-2.3, P < 0.0001) and more severe initial AKI (peak creatinine: 360 vs. Relapses occurred more frequently in cluster 3 (38% vs.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_28","claim":"This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.","citation_support":[],"candidate_sources":[{"study":"Jongsma 2023","year":2023,"doi":"10.1093/ecco-jcc/jjad049","url":"https://doi.org/10.1093/ecco-jcc/jjad049","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Pre- [ n = 86], and 10-14-week post-treatment [ n = 84] sera were collected from patients with moderate-to-severe paediatric CD in the TISKids trial, randomized to FL-IFX [ n = 48; five 5-mg/kg infusions over 22 weeks] or CONV [ n = 43; exclusive enteral nutrition or oral prednisolone]; both groups received azathioprine maintenance. In a large newly diagnosed adult cohort, a five-protein model predicted a subgroup with a high risk for inflammatory bowel disease [IBD] needing treatment escalation [median follow-up, 518 days] 20 ; this model had better accuracy for ulcerative colitis [UC] than for CD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Xie 2025","year":2025,"doi":"10.1038/s41392-025-02252-5","url":"https://doi.org/10.1038/s41392-025-02252-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Manageable grade 3 or 4 treatment-related adverse events developed in 27.3% (12/44) of patients. 6 Similarly, the RATIONALE-312 trial revealed tislelizumab’s clinical benefit, showing enhanced PFS (median 4.7 vs 4.3 months; HR = 0.64, 95% CI 0.52-0.78) and OS outcomes (median 15.5 vs 13.5 months; HR = 0.75, 95% CI 0.61-0.93).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Wallen 2024","year":2024,"doi":"10.3389/fimmu.2024.1413956","url":"https://doi.org/10.3389/fimmu.2024.1413956","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Further, we found younger male patients treated with immunotherapy alone had significantly worse survival compared to male patients ≥65 years, while the addition of chemotherapy reduced this disparity. More than 238,000 new cases of lung cancer were estimated for 2023 in the United States (US), and 85% of cases will be diagnosed as non-small cell lung cancer (NSCLC) ( 1 ).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Hoang 2025","year":2025,"doi":"10.1038/s44319-025-00516-3","url":"https://doi.org/10.1038/s44319-025-00516-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"The muscle mass/body weight was slightly different at steady state, old muscles being 6.1% lighter than young muscles. The cross-sectional area of the regenerating myofibers was decreased at day 7 (-14%) and remained lower at day 28 (-26.3%) post injury in old mice where notably the number of large myofibers was strongly reduced (Figs.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Boudhabhay 2026","year":2026,"doi":"10.1016/j.ekir.2025.103766","url":"https://doi.org/10.1016/j.ekir.2025.103766","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"3.2-2.3, P < 0.0001) and more severe initial AKI (peak creatinine: 360 vs. Relapses occurred more frequently in cluster 3 (38% vs.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_29","claim":"| contextual adjacent evidence | 0 | 1 | null | direct interventional hard-endpoint gap |","citation_support":[],"candidate_sources":[{"study":"Jongsma 2023","year":2023,"doi":"10.1093/ecco-jcc/jjad049","url":"https://doi.org/10.1093/ecco-jcc/jjad049","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Pre- [ n = 86], and 10-14-week post-treatment [ n = 84] sera were collected from patients with moderate-to-severe paediatric CD in the TISKids trial, randomized to FL-IFX [ n = 48; five 5-mg/kg infusions over 22 weeks] or CONV [ n = 43; exclusive enteral nutrition or oral prednisolone]; both groups received azathioprine maintenance. In a large newly diagnosed adult cohort, a five-protein model predicted a subgroup with a high risk for inflammatory bowel disease [IBD] needing treatment escalation [median follow-up, 518 days] 20 ; this model had better accuracy for ulcerative colitis [UC] than for CD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Xie 2025","year":2025,"doi":"10.1038/s41392-025-02252-5","url":"https://doi.org/10.1038/s41392-025-02252-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Manageable grade 3 or 4 treatment-related adverse events developed in 27.3% (12/44) of patients. 6 Similarly, the RATIONALE-312 trial revealed tislelizumab’s clinical benefit, showing enhanced PFS (median 4.7 vs 4.3 months; HR = 0.64, 95% CI 0.52-0.78) and OS outcomes (median 15.5 vs 13.5 months; HR = 0.75, 95% CI 0.61-0.93).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Wallen 2024","year":2024,"doi":"10.3389/fimmu.2024.1413956","url":"https://doi.org/10.3389/fimmu.2024.1413956","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Further, we found younger male patients treated with immunotherapy alone had significantly worse survival compared to male patients ≥65 years, while the addition of chemotherapy reduced this disparity. More than 238,000 new cases of lung cancer were estimated for 2023 in the United States (US), and 85% of cases will be diagnosed as non-small cell lung cancer (NSCLC) ( 1 ).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Hoang 2025","year":2025,"doi":"10.1038/s44319-025-00516-3","url":"https://doi.org/10.1038/s44319-025-00516-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"The muscle mass/body weight was slightly different at steady state, old muscles being 6.1% lighter than young muscles. The cross-sectional area of the regenerating myofibers was decreased at day 7 (-14%) and remained lower at day 28 (-26.3%) post injury in old mice where notably the number of large myofibers was strongly reduced (Figs.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Boudhabhay 2026","year":2026,"doi":"10.1016/j.ekir.2025.103766","url":"https://doi.org/10.1016/j.ekir.2025.103766","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"3.2-2.3, P < 0.0001) and more severe initial AKI (peak creatinine: 360 vs. Relapses occurred more frequently in cluster 3 (38% vs.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_30","claim":"| deficiency prevalence | 0 | 1 | null | direct interventional hard-endpoint gap |","citation_support":[],"candidate_sources":[{"study":"Jongsma 2023","year":2023,"doi":"10.1093/ecco-jcc/jjad049","url":"https://doi.org/10.1093/ecco-jcc/jjad049","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Pre- [ n = 86], and 10-14-week post-treatment [ n = 84] sera were collected from patients with moderate-to-severe paediatric CD in the TISKids trial, randomized to FL-IFX [ n = 48; five 5-mg/kg infusions over 22 weeks] or CONV [ n = 43; exclusive enteral nutrition or oral prednisolone]; both groups received azathioprine maintenance. In a large newly diagnosed adult cohort, a five-protein model predicted a subgroup with a high risk for inflammatory bowel disease [IBD] needing treatment escalation [median follow-up, 518 days] 20 ; this model had better accuracy for ulcerative colitis [UC] than for CD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Xie 2025","year":2025,"doi":"10.1038/s41392-025-02252-5","url":"https://doi.org/10.1038/s41392-025-02252-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Manageable grade 3 or 4 treatment-related adverse events developed in 27.3% (12/44) of patients. 6 Similarly, the RATIONALE-312 trial revealed tislelizumab’s clinical benefit, showing enhanced PFS (median 4.7 vs 4.3 months; HR = 0.64, 95% CI 0.52-0.78) and OS outcomes (median 15.5 vs 13.5 months; HR = 0.75, 95% CI 0.61-0.93).","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Wallen 2024","year":2024,"doi":"10.3389/fimmu.2024.1413956","url":"https://doi.org/10.3389/fimmu.2024.1413956","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Further, we found younger male patients treated with immunotherapy alone had significantly worse survival compared to male patients ≥65 years, while the addition of chemotherapy reduced this disparity. More than 238,000 new cases of lung cancer were estimated for 2023 in the United States (US), and 85% of cases will be diagnosed as non-small cell lung cancer (NSCLC) ( 1 ).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Hoang 2025","year":2025,"doi":"10.1038/s44319-025-00516-3","url":"https://doi.org/10.1038/s44319-025-00516-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"The muscle mass/body weight was slightly different at steady state, old muscles being 6.1% lighter than young muscles. The cross-sectional area of the regenerating myofibers was decreased at day 7 (-14%) and remained lower at day 28 (-26.3%) post injury in old mice where notably the number of large myofibers was strongly reduced (Figs.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Boudhabhay 2026","year":2026,"doi":"10.1016/j.ekir.2025.103766","url":"https://doi.org/10.1016/j.ekir.2025.103766","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"3.2-2.3, P < 0.0001) and more severe initial AKI (peak creatinine: 360 vs. Relapses occurred more frequently in cluster 3 (38% vs.","source_id":"source_5","support_kind":"candidate_source_row"}]}]}},{"name":"claim_graph.json","media_type":"application/json","content":{"publication_id":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","content_hash":"sha256:202614fc145910c5f92e2946e40ee0e67aa8450e60799c65df6fe10268feaa48","nodes":[{"id":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","type":"publication","title":"Research Synthesis: Immune Age — full paper"},{"id":"claim_1","type":"claim","text":"This synthesis tests the thesis that evidence for Immune age is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Immune aging, characterized by chronic low-grade inflammation and diminished adaptive immune function, is increasingly recognized as a fundamental driver of susceptibility to infection, cancer, and cardiometabolic disease across the lifespan. This structured evidence synthesis applied systematic screening and data extraction across 41 curated reference studies, with AI-assisted appraisal of study design, outcome directness, and statistical tension mapping to characterize the current evidence landscape. Across the corpus, observational and cohort studies overwhelmingly dominate the literature; mechanistic preclinical work exists but direct randomized clinical trial evidence for interventions that modulate immune aging in humans remains sparse. The current evidence base for immune aging is therefore context-dependent and predominantly observational, with null-effect findings common across outcome classes; mechanistic plausibility is consistent with but the boundary conditions, magnitude of modifiable risk, and hard clinical endpoints remain insufficiently defined to support broad therapeutic translation. **Evidence-abstraction note."},{"id":"claim_2","type":"claim","text":"This synthesis tests the thesis that evidence for Immune age is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation."},{"id":"claim_3","type":"claim","text":"This structured evidence synthesis applied systematic screening and data extraction across 41 curated reference studies, with AI-assisted appraisal of study design, outcome directness, and statistical tension mapping to characterize the current evidence landscape."},{"id":"claim_4","type":"claim","text":"Across the corpus, observational and cohort studies overwhelmingly dominate the literature; mechanistic preclinical work exists but direct randomized clinical trial evidence for interventions that modulate immune aging in humans remains sparse."},{"id":"claim_5","type":"claim","text":"The current evidence base for immune aging is therefore context-dependent and predominantly observational, with null-effect findings common across outcome classes; mechanistic plausibility is consistent with but the boundary conditions, magnitude of modifiable risk, and hard clinical endpoints remain insufficiently defined to support broad therapeutic translation."},{"id":"claim_6","type":"claim","text":"Evidence-abstraction note.** The 41 retained reference papers are not 41 independent primary clinical trials: 41 are review, indirect, or mechanistic source-level summaries, and no source is classified as direct interventional hard-endpoint evidence, although human observational/prognostic evidence is present. Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence."},{"id":"claim_7","type":"claim","text":"This manuscript is reported as a Evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-immune_age-v06-DAILY-2026-06-02T08-03-13Z`."},{"id":"claim_8","type":"claim","text":"The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text."},{"id":"claim_9","type":"claim","text":"Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`."},{"id":"claim_10","type":"claim","text":"Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, immune, immune and inflammation, longevity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates."},{"id":"claim_11","type":"claim","text":"Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified."},{"id":"claim_12","type":"claim","text":"Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim."},{"id":"claim_13","type":"claim","text":"| Contextual Adjacent Evidence | n=1; claims=2 | no extracted directional signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |"},{"id":"claim_14","type":"claim","text":"This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate."},{"id":"claim_15","type":"claim","text":"27 included sources were assigned to this outcome class. Directional coding: null=27. Directness coding: indirect=25, mechanistic=2."},{"id":"claim_16","type":"claim","text":"8 included sources were assigned to this outcome class. Directional coding: null=8. Directness coding: indirect=7, mechanistic=1."},{"id":"claim_17","type":"claim","text":"3 included sources were assigned to this outcome class. Directional coding: null=3. Directness coding: indirect=3."},{"id":"claim_18","type":"claim","text":"1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1."},{"id":"claim_19","type":"claim","text":"1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1."},{"id":"claim_20","type":"claim","text":"1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1."},{"id":"claim_21","type":"claim","text":"Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim."},{"id":"claim_22","type":"claim","text":"A primary limitation is the absence of large, prospective, randomized controlled trials designed to test immune aging interventions against hard clinical endpoints. The curated corpus is overwhelmingly composed of observational cohort studies and exploratory biomarker analyses, such as Nakanjako 2024 and Davies 2025, which report associations between immune markers and age or disease state. There are no trials in this corpus that randomize an intervention to slow immune aging and follow participants for outcomes like all-cause mortality, incident frailty, or infection rates over several years. Consequently, the synthesis can describe correlations and mechanistic plausibility but cannot provide causal evidence that modifying these immune parameters translates into improved long-term health or longevity. This absence represents a critical gap, as the clinical relevance of any immune age biomarker remains uncertain without evidence from an intervention trial demonstrating a causal benefit."},{"id":"claim_23","type":"claim","text":"The evidence base is also limited by its heavy reliance on findings from single studies for specific outcomes, which precludes internal replication within the corpus. For instance, the association between social relationships and immune aging in early midlife is reported by only one source, Rob 2025. Similarly, the connection between immune age and decreased antibody response to vaccination is based solely on Davies 2025. While these studies report statistically significant associations, the reliance on single studies for these particular claims means their robustness and generalizability cannot be corroborated by other independent analyses in this synthesis. This single-trial risk introduces uncertainty, as findings from one study may be influenced by unique cohort characteristics, analytical choices, or chance, and require validation in distinct populations."},{"id":"claim_24","type":"claim","text":"Finally, the corpus primarily characterizes immune aging through cellular and molecular profiling endpoints, with a notable scarcity of evidence linking these markers to clinically relevant functional outcomes. Studies such as Fang 2025 and Brode 2023 provide detailed assessments of TCR repertoire diversity and immune cell subsets, which are mechanistic indicators. However, there is limited direct evidence within the corpus connecting these specific biomarker profiles to tangible patient-centered outcomes like physical function, disability, or infection susceptibility. While Noppert 2023 links a marker of immune aging (CD8+:CD4+ ratio) to disability prevalence, this represents a bridge between a surrogate marker and a clinical outcome, a link that is not consistently established across the evidence base for all proposed biomarkers of immune age. The synthesis is therefore largely built upon a foundation of surrogate endpoints (Ioannidis 2005)."},{"id":"claim_25","type":"claim","text":"For immune age, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus may support immune age as a general health or lifestyle intervention where otherwise indicated, but does not justify marketing it as a standalone geroprotective or anti-aging intervention with proven hard-longevity effects. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging."},{"id":"claim_26","type":"claim","text":"This synthesis maps 41 included sources on Immune age across 6 outcome classes and 382 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit."},{"id":"claim_27","type":"claim","text":"Across 41 curated reference papers, the evidence base for Immune age shows a context-dependent profile. Null findings dominate: immune inflammation, immune. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Immune age anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established."},{"id":"claim_28","type":"claim","text":"This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary."},{"id":"claim_29","type":"claim","text":"| contextual adjacent evidence | 0 | 1 | null | direct interventional hard-endpoint gap |"},{"id":"claim_30","type":"claim","text":"| deficiency prevalence | 0 | 1 | null | direct interventional hard-endpoint gap |"},{"id":"source_1","type":"source","study":"Jongsma 2023","year":2023,"doi":"10.1093/ecco-jcc/jjad049","url":"https://doi.org/10.1093/ecco-jcc/jjad049","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Pre- [ n = 86], and 10-14-week post-treatment [ n = 84] sera were collected from patients with moderate-to-severe paediatric CD in the TISKids trial, randomized to FL-IFX [ n = 48; five 5-mg/kg infusions over 22 weeks] or CONV [ n = 43; exclusive enteral nutrition or oral prednisolone]; both groups received azathioprine maintenance. In a large newly diagnosed adult cohort, a five-protein model predicted a subgroup with a high risk for inflammatory bowel disease [IBD] needing treatment escalation [median follow-up, 518 days] 20 ; this model had better accuracy for ulcerative colitis [UC] than for CD."},{"id":"source_2","type":"source","study":"Xie 2025","year":2025,"doi":"10.1038/s41392-025-02252-5","url":"https://doi.org/10.1038/s41392-025-02252-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Manageable grade 3 or 4 treatment-related adverse events developed in 27.3% (12/44) of patients. 6 Similarly, the RATIONALE-312 trial revealed tislelizumab’s clinical benefit, showing enhanced PFS (median 4.7 vs 4.3 months; HR = 0.64, 95% CI 0.52-0.78) and OS outcomes (median 15.5 vs 13.5 months; HR = 0.75, 95% CI 0.61-0.93)."},{"id":"source_3","type":"source","study":"Wallen 2024","year":2024,"doi":"10.3389/fimmu.2024.1413956","url":"https://doi.org/10.3389/fimmu.2024.1413956","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Further, we found younger male patients treated with immunotherapy alone had significantly worse survival compared to male patients ≥65 years, while the addition of chemotherapy reduced this disparity. More than 238,000 new cases of lung cancer were estimated for 2023 in the United States (US), and 85% of cases will be diagnosed as non-small cell lung cancer (NSCLC) ( 1 )."},{"id":"source_4","type":"source","study":"Hoang 2025","year":2025,"doi":"10.1038/s44319-025-00516-3","url":"https://doi.org/10.1038/s44319-025-00516-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"The muscle mass/body weight was slightly different at steady state, old muscles being 6.1% lighter than young muscles. The cross-sectional area of the regenerating myofibers was decreased at day 7 (-14%) and remained lower at day 28 (-26.3%) post injury in old mice where notably the number of large myofibers was strongly reduced (Figs."},{"id":"source_5","type":"source","study":"Boudhabhay 2026","year":2026,"doi":"10.1016/j.ekir.2025.103766","url":"https://doi.org/10.1016/j.ekir.2025.103766","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"3.2-2.3, P < 0.0001) and more severe initial AKI (peak creatinine: 360 vs. Relapses occurred more frequently in cluster 3 (38% vs."},{"id":"source_6","type":"source","study":"Nakanjako 2024","year":2024,"doi":"10.1016/j.heliyon.2024.e31910","url":"https://doi.org/10.1016/j.heliyon.2024.e31910","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"In a cross-sectional comparative study of HIV-infected adults with CD4≥500 cells/μl after at least 12 years of suppressive ART and age-and-gender-matched HIV-negative individuals, immune activation and immune aging phenotypes were measured, using multi-color flowcytometry. ART-treated HIV-infected individuals had higher body mass index (P = 0.004), waist-hip circumference (P = 0.041), hip circumference (P < 0.001), and diastolic blood pressure (P = 0.012) and immune activation (CD4 + CD38+HLADR+; median 4.15,IQR(1.030,14.6)] relative to the HIV-negative age-matched individuals [median 3.14,IQR(1.030, 6.68)]; P=0.0034."},{"id":"source_7","type":"source","study":"Ledee 2025","year":2025,"doi":"10.3389/fimmu.2025.1523871","url":"https://doi.org/10.3389/fimmu.2025.1523871","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"The mITT analysis showed a significant increase in LBR with precision care compared to conventional care (29.7% vs. 39.6%; OR: 2.12 [1.02-4.41]) or those with a history of two or more failed ET (LBR: 23.4% vs."},{"id":"source_8","type":"source","study":"Fang 2025","year":2025,"doi":"10.1111/acel.14460","url":"https://doi.org/10.1111/acel.14460","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Consequently, there is a pressing need for more comprehensive examinations of IR profiles spanning the entire age range of 0-18 years, to better understand pediatric immune development and its implications for health and disease. We examined a cohort of 325 healthy Chinese children aged 0-18 years, finding a marked decrease in TCRβ diversity with advancing age, showing a significant negative correlation."},{"id":"source_9","type":"source","study":"Levy 2024","year":2024,"doi":"10.1186/s12943-024-01970-8","url":"https://doi.org/10.1186/s12943-024-01970-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"To test in each cohort, the hypothesis that the PFS rate is greater than p0 = 15% with alpha = 0.033 and with a 90% power to detect activity greater than p1 = 32%, 54 evaluable patients should be enrolled. In patients undergoing testing, 11 (34%) had results positive for PD-L1 (≥ 1%) and 15 (52%) had CD8 T-cell infiltration of greater than 2.5%."},{"id":"source_10","type":"source","study":"Davies 2025","year":2025,"doi":"10.1038/s41598-025-04736-4","url":"https://doi.org/10.1038/s41598-025-04736-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"We observed that individuals aged > 60 years demonstrated a higher immune ‘age’ as calculated by IMMAX score (0.75 compared with 0.48 for individuals aged < 35 years; p = < 0.0001). Immune age negatively correlated with IgG responsivity in older individuals with recent prior exposure to SARS-CoV-2 (b = -0.01; p = 0.05)."},{"id":"source_11","type":"source","study":"Qiao 2025","year":2025,"doi":"10.3389/fimmu.2025.1623319","url":"https://doi.org/10.3389/fimmu.2025.1623319","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Furthermore, a study published in 2023 projected that the prevalence of COPD among individuals aged 25 years and older would increase by 23% from 2020 to 2050 ( 4 ). The frequency of circulating Tfh cells, which constituted approximately 4% of CD4 + T cells in stage1, decreased to ~2% in stages 3-4 ( Figure 3E )."},{"id":"source_12","type":"source","study":"Perlmutter 2024","year":2024,"doi":"10.3389/fnut.2024.1474597","url":"https://doi.org/10.3389/fnut.2024.1474597","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"With specific regard to the polyphenol content of Tartary buckwheat, it is notable that the seed contains up to 2.42% flavonoid polyphenolic content by weight ( 35 ), compared to a significantly lower content in wheat 0.84% ( 36 ). We hypothesize that consumption of a polyphenol concentrate based on the makeup of Tartary buckwheat over 90 days will lead to significant changes in the epigenetic methylation patterns and immune cell phenotypes in healthy adults, as measured by epigenetic age clocks and immune markers, potentially contributing to enhanced immune function and longevity-related physiological pathways."},{"id":"source_13","type":"source","study":"Zuroff 2022","year":2022,"doi":"10.1016/j.ebiom.2022.104179","url":"https://doi.org/10.1016/j.ebiom.2022.104179","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"While most CD4 and CD8 T-cell aging trajectories were similar between groups, MS patients exhibited abnormal age-associated increases of activated (HLA-DR + CD38 + ; ( P = 0.013) and cytotoxic CD4 T cells, particularly in patients >60 (EOMES: P < 0.001). A fluctuation score was calculated for each parameter according to the following equation: Fluctuation score = ((Vn - M)/M)*100%, where Vn is the value of the parameter for the internal control in each batch and M is the mean of the parameter from all batches."},{"id":"source_14","type":"source","study":"Rob 2025","year":2025,"doi":"10.1016/j.bbih.2025.100993","url":"https://doi.org/10.1016/j.bbih.2025.100993","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"We examined associations between social relationships, in terms of quantity (Social Network Index, Close Contacts Index) and quality of relationships (spouse/partner, friends, and family members), and immune aging in a U.S-representative early midlife population (age 33-44) from Wave V of the National Longitudinal Study of Adolescent to Adult Health (n = 4451). Furthermore, we calculated the median CD4 + memory:naïve, CD8 + memory:naïve, and CD8+:CD4+ T cell ratios and 95 % confidence intervals, by age group, sex, race/ethnicity, educational attainment, inflammatory condition, smoking status, BMI, depression, and social relationship measures."},{"id":"source_15","type":"source","study":"Nawrocki 2023","year":2023,"doi":"10.1158/1078-0432.CCR-23-0229","url":"https://doi.org/10.1158/1078-0432.CCR-23-0229","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Six (55%) of 11 response-evaluable patients showed decreased paraprotein. Patients were excluded if they had current evidence of intracranial disease; were diagnosed or treated for any malignancy other than myeloma within 2 years prior to the first dose; received autologous stem cell transplantation within 3 months prior to enrollment or allogeneic stem cell transplantation at any time; or had grade 2 or higher peripheral neuropathy."},{"id":"source_16","type":"source","study":"Stark 2024","year":2024,"doi":"10.1186/s42523-024-00318-3","url":"https://doi.org/10.1186/s42523-024-00318-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Horizontal lines indicate statistically significant differences between mouse lines as assessed by Mann-Whitney test: * p < 0.05; *** p < 0.001; **** p < 0.0001 The egg of S. mansoni secretes molecules that induce immune cell recruitment, inflammation and fibrosis that ultimately lead to granuloma formation [ 19 ]. Asterisks indicate significant differences (as determined by ANOVA) between Sm + and Sm- of the same line, and hash symbols between Sm + of both mouse lines: * p < 0.01, **/ ## p < 0.001, ***/ ### p < 0.001 Comparable antibody kynetics in Sm + D2 HMA and WT mice suggest that systemic humoral responses against S. mansoni are independent of baseline gut microbiota composition, thus supporting our previous observations [ 23 ] and indicating that the higher worm burdens observed in Sm + D2 HMA are unlikely to be attributable to deficient or altered antibody responses in animals ha"},{"id":"source_17","type":"source","study":"Liu 2025","year":2025,"doi":"10.1111/acel.70050","url":"https://doi.org/10.1111/acel.70050","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Over the past 200 years, life expectancy has risen due to medical advances, along with the emergence of medical and social challenges related to aging. In clinical trials, supplementation with 0.2 and 0.3 mg/kg of PQQ has been shown to effectively enhance the body's antioxidant capacity and reduce systemic inflammation in human subjects (Harris et al."},{"id":"source_18","type":"source","study":"Arjmand 2026","year":2026,"doi":"10.1038/s41398-026-04037-y","url":"https://doi.org/10.1038/s41398-026-04037-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Deviation 95% Confidence Interval Mean Lower Upper Sex (F/M) HCs 90 (42/48) 0.136 - - - - FEPs 113 (41/72) - - - - Age HCs 90 0.006 37.66 14.22 34.68 40.63 FEPs 113 31.94 10.03 30.07 33.80 BMI (kg/m 2 ) HCs 88 0.920 24.68 3.58 23.92 25.44 FEPs 111 24.69 4.25 23.89 25.49 Nicotine use HCs 88 (15/88) 0.020 - - - - FEPs 87 (29/87) - - - - PANSS Positive HCs NA FEPs 90 17.61 6.12 16.33 18.89 PANSS Negative HCs NA FEPs 90 16.50 6.59 15.12 17.88 PANSS General HCs NA FEPs 90 35.99 10.48 33.79 38.18 PANSS Total HCs NA FEPs 90 70.10 18.99 66.12 74.08 GAF-S HCs 52 84.58 7.71 82.43 86.72 FEPs 67 33.63 10.34 31.10 36.15 GAF-F HCs 52 85.11 7.17 83.12 87.11 FEPs 67 41.82 13.07 38.63 45.01 CGI HCs NA FEPs 72 4.53 1.20 4.25 4.81 DUP (Months) HCs NA FEPs 58 11.26 6.56 15.95 17.85 PANSS , Positive and Negative Syndrome Scale; GAF , Global Assessment of Functioning (Symptoms and Function); CGI , Clinical Gl"},{"id":"source_19","type":"source","study":"Trebing 2025","year":2025,"doi":"10.3389/fragi.2025.1716985","url":"https://doi.org/10.3389/fragi.2025.1716985","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"A five-year follow-up in 53 participants from a cohort study showed an average IMMAX increase of +0.02, equivalent to an additional 4.8 years of chronological age, according to Bröde’s percentile model ( Bröde et al., 2023 ). Additional exclusion criteria were <10 days since last infection or vaccination with an inactivated vaccine or <4 weeks since vaccination with attenuated live vaccine."},{"id":"source_20","type":"source","study":"Brode 2022","year":2022,"doi":"10.3390/biology11111576","url":"https://doi.org/10.3390/biology11111576","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"CRF was determined by submaximal bicycle ergometer testing in a cross-sectional sample of 597 volunteers aged 20-70 years from the ’Dortmund Vital Study’ (DVS, ClinicalTrials.gov Identifier: NCT05155397 ). Low CRF was scored if the ergometer test was not completed due to medical reasons or if the power output projected to a heart rate of 130 bpm divided by body mass was below sex-specific reference values of 1.25 W/kg for females and 1.5 W/kg for males, respectively."},{"id":"source_21","type":"source","study":"Li 2025","year":2025,"doi":"10.1038/s43587-025-00819-z","url":"https://doi.org/10.1038/s43587-025-00819-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Cells with less than 200 or greater than 5,000 features and with mitochondrial percentage greater than 25% were excluded. Four MMR-vaccinated individuals and five placebo-vaccinated individuals aged below 30 years were included in this study."},{"id":"source_22","type":"source","study":"Karakaslar 2023","year":2023,"doi":"10.1111/acel.13792","url":"https://doi.org/10.1111/acel.13792","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Most aging studies utilize the long‐living laboratory strain C57BL/6J (B6) with a median life span of 901 days for males and 866 days for females (Yuan et al., 2009 ). First, similar to humans, NZO females live longer than males (Austad & Fischer, 2016 ), where the median lifespan is 576 days for females and 423 days for males (Yuan et al., 2009 )."},{"id":"source_23","type":"source","study":"Shin 2022","year":2022,"doi":"10.1111/acel.13702","url":"https://doi.org/10.1111/acel.13702","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Indeed, over half of the people in the United States with HIV are aged 50 years or older, and this number is expected to increase to 70% by the year 2030 (Wing, 2016 ). Here, we investigated the effect of HIV infection on immune aging by analyzing a set of aging‐associated genes in peripheral blood mononuclear cells (PBMCs) as well as by performing high‐dimensional T‐cell analysis in older healthy living HIV‐infected individuals (age ≥65 years) without viremia on ART and control groups, including older HIV‐uninfected healthy living and frail individuals (age ≥65 years)."},{"id":"source_24","type":"source","study":"Brode 2025","year":2025,"doi":"10.3390/biom16010055","url":"https://doi.org/10.3390/biom16010055","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"For evaluating a potential role of latent T. gondii infection in immunological aging, we determined T. gondii antibody levels and immunosenescence biomarkers in a cross-sectional sample of 584 volunteers aged 20-70 years from the Dortmund Vital Study (ClinicalTrials.gov Identifier NCT05155397 ) representing the regional population. One-hundred-sixty-one participants were seropositive, representing an overall 28% latent T. gondii seroprevalence, which did not significantly differ between males and females, but increased with age."},{"id":"source_25","type":"source","study":"Qing 2024","year":2024,"doi":"10.1007/s00277-023-05603-w","url":"https://doi.org/10.1007/s00277-023-05603-w","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Baseline CD38 expression levels on tumor tissues were evaluable in 21 patients (responders, n = 6; nonresponders, n = 15), baseline plasma EBV-DNA levels were evaluable in 23 patients (responders, n = 7; nonresponders, n = 16), and baseline T cell, B cell, and NK cell counts and other immune profiling results were evaluable in 23 patients (responders, n = 7; nonresponders, n = 16). MPFC, multiparameter flow cytometry; NK, natural killer; PB, peripheral blood; C, cycle; D, day; EOT, end of treatment; T reg , regulatory T cell; MDSC, myeloid-derived suppressor cell; m-MDSC, monocytic myeloid-derived suppressor cell; g-MDSC, granulocyte-like myeloid derived suppressor cell. * P < 0.05; ** P < 0.005; *** P < 0.0005 CyTOF analyses, which allowed a deep dive into cellular components of the NKTCL-patient peripheral immune response, confirmed a higher percentage of B cells at baseline in respond"},{"id":"source_26","type":"source","study":"Ma 2026","year":2026,"doi":"10.3389/fimmu.2026.1742646","url":"https://doi.org/10.3389/fimmu.2026.1742646","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Because of refractory progression under standard management, immune testing obtained at 31 +1 weeks showed elevated TNF-α, low complement C4, weak ANA positivity, and T/B-cell imbalance (descriptive findings in this single case). Over the subsequent week, proteinuria decreased by >50% (10.78 to 4.99 g/24 h), blood pressure improved to 100-120/60-80 mmHg, and edema regressed."},{"id":"source_27","type":"source","study":"Samuelsen 2024","year":2024,"doi":"10.1097/CCE.0000000000001106","url":"https://doi.org/10.1097/CCE.0000000000001106","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Each pg/mL increase in IL-6 concentration at 4 and 18 hours post-stimulation corresponded to a decrease in SOFA scores 2 days later. For TNF, the association was more pronounced, compared with IL-6; higher levels of TNF at 4 hours were linked with a substantial reduction in SOFA d3 scores (by -0.183 points; 95% CI, -0.339 to -0.027; p = 0.022), and this significant negative correlation also persisted at 18 hours (-0.090 ; 95% CI, -0.171 to -0.009 ; p = 0.031)."},{"id":"source_28","type":"source","study":"Qu 2022","year":2022,"doi":"10.1038/s41390-022-02203-8","url":"https://doi.org/10.1038/s41390-022-02203-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"8 years, p > 0.05) between the Control - , Control + , SIDS - , and SIDS + groups (Table 3 ). Detailed statistical analyses revealed no significant differences for these proteins except for the pro-inflammatory chemokine CCL5, (Table 5 ) that was higher in the SIDS + group ( p = 0.020)."},{"id":"source_29","type":"source","study":"Hu 2024","year":2024,"doi":"10.1038/s41467-024-52522-z","url":"https://doi.org/10.1038/s41467-024-52522-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Previous work, including ours, have demonstrated that TCRs clustered using such strategy are highly specific (> = 95%) to the same antigen epitopes 69 , with smaller ( n < = 5) clusters being more likely to share antigen-specificity 68 . A total of 75,820 T cells passed quality control, with a mitochondrial gene percentage of less than 5% and a ribosomal gene ratio of less than 2%, allowing them to proceed to downstream analysis."},{"id":"source_30","type":"source","study":"Govind 2024","year":2024,"doi":"10.1186/s12979-024-00490-9","url":"https://doi.org/10.1186/s12979-024-00490-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"The study population comprised 700 randomly recruited age-stratified individuals from the general population covering the age range 35-74 years (“RASIG”) which were part of a larger cross-sectional study cohort recruited by the MARK-AGE consortium [ 30 - 33 ] ( http://www.mark-age.eu ). 1 Percentage of positive samples in the urine of males (unshaded bars) and females (shaded bars) between the ages of 35 and 74 Table 1 Females Age range n undetectable % positive % HHV5 % HHV6a % HHV6b % HHV7 % 35-44 75 34 45 41 55 24 59 16 39 3 7 19 46 45-54 68 32 47 36 53 22 61 12 33 10 28 15 42 55-64 68 28 41 40 59 30 75 21 53 6 15 16 40 65-74 71 28 39 43 61 22 51 15 35 6 14 21 49 total 282 122 43 160 57 98 61 15 9 25 16 71 44 Table 2 Males Age range n undetectable % positive % HHV5 % HHV6a % HHV6b % HHV7 % 35-44 70 37 53 33 47 19 58 13 39 4 12 10 30 45-54 69 31 45 38 55 24 63 16 42 5 13 12 32 55-64 78"},{"id":"source_31","type":"source","study":"Roy 2023","year":2023,"doi":"10.7554/eLife.86136","url":"https://doi.org/10.7554/eLife.86136","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Buffy coat, PBMCs, and granulocytes were collected from Genetic and Epigenetic Signatures of Translational Aging Laboratory Testing study (GESTALT) study participants ( N = 55; 34 men and 21 women; age 22-83 years) who were free of diseases (except controlled hypertension or history of cancer silent for >10 years), not on medications (except one antihypertensive drug), had no physical or cognitive impairments, non-smokers, weighed >110 lbs, had body mass index <30 kg/m 2 ( Roy et al., 2021 ; Ubaida-Mohien et al., 2019 ). Transcripts were aggregated to genes with tximport and filtered out if less than 10 TPM were detected in more than 33% of the samples."},{"id":"source_32","type":"source","study":"Brode 2023","year":2023,"doi":"10.3390/ijms241713186","url":"https://doi.org/10.3390/ijms241713186","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"For 1605 individuals (18-97 years), we determined the comprehensive immune age index IMMAX from flow-cytometry-based blood cell sub-populations and identified age-specific centiles by fitting generalized additive models for location, scale, and shape. Aiming at a comprehensive database for estimating age-dependent centiles of immunosenescence biomarkers, we combined the published raw data from the IMM-AGE study (N = 434) [ 11 ] with corresponding own measurements from the baseline examinations of the ongoing longitudinal Dortmund Vital Study (DVS, N = 597) [ 20 ] and a recent study concerning the efficacy of vaccination against SARS-CoV-2 (VAC, N = 574) [ 22 ]."},{"id":"source_33","type":"source","study":"Liu 2023","year":2023,"doi":"10.1097/HEP.0000000000000590","url":"https://doi.org/10.1097/HEP.0000000000000590","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Heatmap showing the interaction strength between the monocyte/macrophage subtypes and remaining immune cells (right). (C) Bubble plot showing major differential ligand‒receptor pairs involved in monocytes/macrophages signaling to neutrophils, showing intensity in either young (red) or aged (blue) mice. (D) Representative flow cytometry plots of CXCR2 + Ly6G + cells (CXCR2 + neutrophils) in the liver tissues of mice in the suckling, young, and aged periods (left, n=3). Aged mice were pretreated with CLLs to deplete macrophages for 48 h, and the HIRI model was subsequently established, followed by a single intrasplenic injection of young intrahepatic macrophages (Y→A chimera, n = 4). (B) Histology (H&E staining, upper), TUNEL staining (middle), and IHC staining for Ly6G (lower) in liver tissues in each group."},{"id":"source_34","type":"source","study":"Le 2025","year":2025,"doi":"10.3390/cells14221793","url":"https://doi.org/10.3390/cells14221793","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Approximately 80% of CVD-related deaths occur in those 65 or older, and CVD mortality nearly doubles when comparing 65-74 years olds to those older than 75 years [ 1 ]. Individuals ≥65 years of age show increased morbidity and mortality after infection with respiratory viruses, including influenza and SARS-CoV-2 [ 4 , 9 , 10 ]."},{"id":"source_35","type":"source","study":"Peronnet 2023","year":2023,"doi":"10.1097/CCM.0000000000005832","url":"https://doi.org/10.1097/CCM.0000000000005832","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Concordance between monocyte expression of human leukocyte antigen-DR (mHLA-DR) and immune profiling panel (IPP) classification in the test set, including healthy volunteers ( n = 510). For comparison, a logistic regression model using only CD74 mRNA expression as a single surrogate of mHLA-DR ( 17 ) had lower performance (AUC 0.77 [95% CI 0.73-0.81]), illustrating the significant contribution of the IPP gene set."},{"id":"source_36","type":"source","study":"Noppert 2025","year":2025,"doi":"10.1093/geroni/igaf122.2016","url":"https://doi.org/10.1093/geroni/igaf122.2016","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Health and Retirement Study (HRS), we examined associations between early life trauma and five markers of immunosenescence among adults aged 60 + (n = 8,373). For instance, women reporting 3+ traumas had a 0.19 higher standardized value of CD4+ EMRA:Naïve (95% CI: 0.08, 0.14) and a 0.16 higher CD8+ EMRA:CD4+ Naïve ratio (95% CI: 0.05, 0.27), adjusting for age."},{"id":"source_37","type":"source","study":"Rousseau 2025","year":2025,"doi":"10.1186/s12929-025-01146-6","url":"https://doi.org/10.1186/s12929-025-01146-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"In fact, among all immune cells, the decrease in naïve CD8+ T cells is the most significant, with a reduction from 7 to 3% [ 7 ]. Interestingly, a recent study showed that murine memory T cells iteratively boosted with vaccination and transferred into new hosts over the course of 10 years in a multi lifetime model [ 26 ] are able to preserve telomere length and present hypermethylation in cell cycle control genes Cdkn2a (p19Arf, p16Ink4a) and Cdkn2b (p15Ink4b), with concomitant demethylation of proliferation drivers like CDK6 and Rb1 [ 27 ]."},{"id":"source_38","type":"source","study":"Kapse 2024","year":2024,"doi":"10.3389/frtra.2024.1356948","url":"https://doi.org/10.3389/frtra.2024.1356948","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"The median age of lung transplant recipients continues to increase, rising from 46 to 60 years over the past 20 years ( 11 )."},{"id":"source_39","type":"source","study":"Noppert 2023","year":2023,"doi":"10.1093/geroni/igad104.1007","url":"https://doi.org/10.1093/geroni/igad104.1007","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Among women, we found a one standard deviation increase in the CD8+:CD4+ ratio, a marker of advanced immune aging, was associated with a 24% greater prevalence of ADL disability (PR= 1.24, 95% CI: 1.23, 1.25)."},{"id":"source_40","type":"source","study":"Aitella 2026","year":2026,"doi":"10.3390/ijms27031206","url":"https://doi.org/10.3390/ijms27031206","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Even in very recent real-life cohorts of patients treated with omalizumab or dupilumab, respectively for chronic spontaneous urticaria and for Th2-mediated inflammatory respiratory involvement, or atopic dermatitis, and prurigo nodularis, the mean ± standard deviation and the median age are well below 65 years [ 174 , 175 ]."},{"id":"source_41","type":"source","study":"Zhang 2025","year":2025,"doi":"10.1136/jitc-2025-012432","url":"https://doi.org/10.1136/jitc-2025-012432","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Although higher PD-L1 TPS scores have correlated with incremental responses in clinical trials of ICI in NSCLC, PD-L1 IHC positivity is predictive of response in less than 50% of patients."}],"edges":[{"from":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","to":"claim_1","type":"contains_claim"},{"from":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","to":"claim_2","type":"contains_claim"},{"from":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","to":"claim_3","type":"contains_claim"},{"from":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","to":"claim_4","type":"contains_claim"},{"from":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","to":"claim_5","type":"contains_claim"},{"from":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","to":"claim_6","type":"contains_claim"},{"from":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","to":"claim_7","type":"contains_claim"},{"from":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","to":"claim_8","type":"contains_claim"},{"from":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","to":"claim_9","type":"contains_claim"},{"from":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","to":"claim_10","type":"contains_claim"},{"from":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","to":"claim_11","type":"contains_claim"},{"from":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","to":"claim_12","type":"contains_claim"},{"from":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","to":"claim_13","type":"contains_claim"},{"from":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","to":"claim_14","type":"contains_claim"},{"from":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","to":"claim_15","type":"contains_claim"},{"from":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","to":"claim_16","type":"contains_claim"},{"from":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","to":"claim_17","type":"contains_claim"},{"from":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","to":"claim_18","type":"contains_claim"},{"from":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","to":"claim_19","type":"contains_claim"},{"from":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","to":"claim_20","type":"contains_claim"},{"from":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","to":"claim_21","type":"contains_claim"},{"from":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","to":"claim_22","type":"contains_claim"},{"from":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","to":"claim_23","type":"contains_claim"},{"from":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","to":"claim_24","type":"contains_claim"},{"from":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","to":"claim_25","type":"contains_claim"},{"from":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","to":"claim_26","type":"contains_claim"},{"from":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","to":"claim_27","type":"contains_claim"},{"from":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","to":"claim_28","type":"contains_claim"},{"from":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","to":"claim_29","type":"contains_claim"},{"from":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","to":"claim_30","type":"contains_claim"}],"screening":{"identified":41,"screened":41,"excluded":0,"included":41,"included_or_retained":41,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"41 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}},{"name":"contradiction_map.json","media_type":"application/json","content":{"publication_id":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","screening":{"identified":41,"screened":41,"excluded":0,"included":41,"included_or_retained":41,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"41 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["This synthesis tests the thesis that evidence for Immune age is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Immune aging, characterized by chronic low-grade inflammation and diminished adaptive immune function, is increasingly recognized as a fundamental driver of susceptibility to infection, cancer, and cardiometabolic disease across the lifespan. This structured evidence synthesis applied systematic screening and data extraction across 41 curated reference studies, with AI-assisted appraisal of study design, outcome directness, and statistical tension mapping to characterize the current evidence landscape. Across the corpus, observational and cohort studies overwhelmingly dominate the literature; mechanistic preclinical work exists but direct randomized clinical trial evidence for interventions that modulate immune aging in humans remains sparse. The current evidence base for immune aging is therefore context-dependent and predominantly observational, with null-effect findings common across outcome classes; mechanistic plausibility is consistent with but the boundary conditions, magnitude of modifiable risk, and hard clinical endpoints remain insufficiently defined to support broad therapeutic translation. **Evidence-abstraction note.","Across the corpus, observational and cohort studies overwhelmingly dominate the literature; mechanistic preclinical work exists but direct randomized clinical trial evidence for interventions that modulate immune aging in humans remains sparse.","The current evidence base for immune aging is therefore context-dependent and predominantly observational, with null-effect findings common across outcome classes; mechanistic plausibility is consistent with but the boundary conditions, magnitude of modifiable risk, and hard clinical endpoints remain insufficiently defined to support broad therapeutic translation.","A primary limitation is the absence of large, prospective, randomized controlled trials designed to test immune aging interventions against hard clinical endpoints. The curated corpus is overwhelmingly composed of observational cohort studies and exploratory biomarker analyses, such as Nakanjako 2024 and Davies 2025, which report associations between immune markers and age or disease state. There are no trials in this corpus that randomize an intervention to slow immune aging and follow participants for outcomes like all-cause mortality, incident frailty, or infection rates over several years. Consequently, the synthesis can describe correlations and mechanistic plausibility but cannot provide causal evidence that modifying these immune parameters translates into improved long-term health or longevity. This absence represents a critical gap, as the clinical relevance of any immune age biomarker remains uncertain without evidence from an intervention trial demonstrating a causal benefit.","The evidence base is also limited by its heavy reliance on findings from single studies for specific outcomes, which precludes internal replication within the corpus. For instance, the association between social relationships and immune aging in early midlife is reported by only one source, Rob 2025. Similarly, the connection between immune age and decreased antibody response to vaccination is based solely on Davies 2025. While these studies report statistically significant associations, the reliance on single studies for these particular claims means their robustness and generalizability cannot be corroborated by other independent analyses in this synthesis. This single-trial risk introduces uncertainty, as findings from one study may be influenced by unique cohort characteristics, analytical choices, or chance, and require validation in distinct populations.","Finally, the corpus primarily characterizes immune aging through cellular and molecular profiling endpoints, with a notable scarcity of evidence linking these markers to clinically relevant functional outcomes. Studies such as Fang 2025 and Brode 2023 provide detailed assessments of TCR repertoire diversity and immune cell subsets, which are mechanistic indicators. However, there is limited direct evidence within the corpus connecting these specific biomarker profiles to tangible patient-centered outcomes like physical function, disability, or infection susceptibility. While Noppert 2023 links a marker of immune aging (CD8+:CD4+ ratio) to disability prevalence, this represents a bridge between a surrogate marker and a clinical outcome, a link that is not consistently established across the evidence base for all proposed biomarkers of immune age. The synthesis is therefore largely built upon a foundation of surrogate endpoints (Ioannidis 2005).","For immune age, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus may support immune age as a general health or lifestyle intervention where otherwise indicated, but does not justify marketing it as a standalone geroprotective or anti-aging intervention with proven hard-longevity effects. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.","Across 41 curated reference papers, the evidence base for Immune age shows a context-dependent profile. Null findings dominate: immune inflammation, immune. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Immune age anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established."]}},{"name":"evidence_table.csv","media_type":"text/csv","content":"study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness\r\nJongsma 2023,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nXie 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nWallen 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nHoang 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nBoudhabhay 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nNakanjako 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nLedee 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nFang 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nLevy 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nDavies 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nQiao 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nPerlmutter 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nZuroff 2022,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nRob 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nNawrocki 2023,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nStark 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nLiu 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nArjmand 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nTrebing 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nBrode 2022,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nLi 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nKarakaslar 2023,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nShin 2022,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nBrode 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nQing 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nMa 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nSamuelsen 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nQu 2022,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nHu 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nGovind 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nRoy 2023,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nBrode 2023,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nLiu 2023,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nLe 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nPeronnet 2023,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nNoppert 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nRousseau 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nKapse 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nNoppert 2023,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nAitella 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nZhang 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\n"},{"name":"risk_of_bias.json","media_type":"application/json","content":{"publication_id":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","method_note":"Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.","sources":[{"study":"Jongsma 2023","doi":"10.1093/ecco-jcc/jjad049","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Xie 2025","doi":"10.1038/s41392-025-02252-5","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Wallen 2024","doi":"10.3389/fimmu.2024.1413956","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Hoang 2025","doi":"10.1038/s44319-025-00516-3","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Boudhabhay 2026","doi":"10.1016/j.ekir.2025.103766","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Nakanjako 2024","doi":"10.1016/j.heliyon.2024.e31910","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Ledee 2025","doi":"10.3389/fimmu.2025.1523871","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Fang 2025","doi":"10.1111/acel.14460","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Levy 2024","doi":"10.1186/s12943-024-01970-8","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Davies 2025","doi":"10.1038/s41598-025-04736-4","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Qiao 2025","doi":"10.3389/fimmu.2025.1623319","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Perlmutter 2024","doi":"10.3389/fnut.2024.1474597","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Zuroff 2022","doi":"10.1016/j.ebiom.2022.104179","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Rob 2025","doi":"10.1016/j.bbih.2025.100993","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Nawrocki 2023","doi":"10.1158/1078-0432.CCR-23-0229","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Stark 2024","doi":"10.1186/s42523-024-00318-3","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Liu 2025","doi":"10.1111/acel.70050","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Arjmand 2026","doi":"10.1038/s41398-026-04037-y","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Trebing 2025","doi":"10.3389/fragi.2025.1716985","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Brode 2022","doi":"10.3390/biology11111576","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Li 2025","doi":"10.1038/s43587-025-00819-z","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Karakaslar 2023","doi":"10.1111/acel.13792","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Shin 2022","doi":"10.1111/acel.13702","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Brode 2025","doi":"10.3390/biom16010055","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Qing 2024","doi":"10.1007/s00277-023-05603-w","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Ma 2026","doi":"10.3389/fimmu.2026.1742646","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Samuelsen 2024","doi":"10.1097/CCE.0000000000001106","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Qu 2022","doi":"10.1038/s41390-022-02203-8","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Hu 2024","doi":"10.1038/s41467-024-52522-z","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Govind 2024","doi":"10.1186/s12979-024-00490-9","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Roy 2023","doi":"10.7554/eLife.86136","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Brode 2023","doi":"10.3390/ijms241713186","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Liu 2023","doi":"10.1097/HEP.0000000000000590","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Le 2025","doi":"10.3390/cells14221793","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Peronnet 2023","doi":"10.1097/CCM.0000000000005832","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Noppert 2025","doi":"10.1093/geroni/igaf122.2016","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Rousseau 2025","doi":"10.1186/s12929-025-01146-6","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Kapse 2024","doi":"10.3389/frtra.2024.1356948","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Noppert 2023","doi":"10.1093/geroni/igad104.1007","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Aitella 2026","doi":"10.3390/ijms27031206","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Zhang 2025","doi":"10.1136/jitc-2025-012432","risk_of_bias":"not appraised in public sidecar","directness":"primary"}]}}]}